A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.
Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts.
Leukemia induced experimentally in animals by exposure to leukemogenic agents, such as VIRUSES; RADIATION; or by TRANSPLANTATION of leukemic tissues.
Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
Species of GAMMARETROVIRUS, containing many well-defined strains, producing leukemia in mice. Disease is commonly induced by injecting filtrates of propagable tumors into newborn mice.
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.
A malignant disease of the T-LYMPHOCYTES in the bone marrow, thymus, and/or blood.
An acute myeloid leukemia in which 80% or more of the leukemic cells are of monocytic lineage including monoblasts, promonocytes, and MONOCYTES.
A strain of Murine leukemia virus (LEUKEMIA VIRUS, MURINE) arising during the propagation of S37 mouse sarcoma, and causing lymphoid leukemia in mice. It also infects rats and newborn hamsters. It is apparently transmitted to embryos in utero and to newborns through mother's milk.
A neoplastic disease of the lymphoreticular cells which is considered to be a rare type of chronic leukemia; it is characterized by an insidious onset, splenomegaly, anemia, granulocytopenia, thrombocytopenia, little or no lymphadenopathy, and the presence of "hairy" or "flagellated" cells in the blood and bone marrow.
A malignant disease of the B-LYMPHOCYTES in the bone marrow and/or blood.
The type species of DELTARETROVIRUS that causes a form of bovine lymphosarcoma (ENZOOTIC BOVINE LEUKOSIS) or persistent lymphocytosis.
A species of GAMMARETROVIRUS causing leukemia, lymphosarcoma, immune deficiency, or other degenerative diseases in cats. Several cellular oncogenes confer on FeLV the ability to induce sarcomas (see also SARCOMA VIRUSES, FELINE).
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in leukemia.
Leukemia produced by exposure to IONIZING RADIATION or NON-IONIZING RADIATION.
Myeloid-lymphoid leukemia protein is a transcription factor that maintains high levels of HOMEOTIC GENE expression during development. The GENE for myeloid-lymphoid leukemia protein is commonly disrupted in LEUKEMIA and combines with over 40 partner genes to form FUSION ONCOGENE PROTEINS.
An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.
An acute leukemia exhibiting cell features characteristic of both the myeloid and lymphoid lineages and probably arising from MULTIPOTENT STEM CELLS.
A strain of Murine leukemia virus (LEUKEMIA VIRUS, MURINE) producing leukemia of the reticulum-cell type with massive infiltration of liver, spleen, and bone marrow. It infects DBA/2 and Swiss mice.
A promyelocytic cell line derived from a patient with ACUTE PROMYELOCYTIC LEUKEMIA. HL-60 cells lack specific markers for LYMPHOID CELLS but express surface receptors for FC FRAGMENTS and COMPLEMENT SYSTEM PROTEINS. They also exhibit phagocytic activity and responsiveness to chemotactic stimuli. (From Hay et al., American Type Culture Collection, 7th ed, pp127-8)
Aggressive T-Cell malignancy with adult onset, caused by HUMAN T-LYMPHOTROPIC VIRUS 1. It is endemic in Japan, the Caribbean basin, Southeastern United States, Hawaii, and parts of Central and South America and sub-Saharan Africa.
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
An acute myeloid leukemia in which 20-30% of the bone marrow or peripheral blood cells are of megakaryocyte lineage. MYELOFIBROSIS or increased bone marrow RETICULIN is common.
A strain of Murine leukemia virus (LEUKEMIA VIRUS, MURINE) isolated from spontaneous leukemia in AKR strain mice.
Translation products of a fusion gene derived from CHROMOSOMAL TRANSLOCATION of C-ABL GENES to the genetic locus of the breakpoint cluster region gene on chromosome 22. Several different variants of the bcr-abl fusion proteins occur depending upon the precise location of the chromosomal breakpoint. These variants can be associated with distinct subtypes of leukemias such as PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; and NEUTROPHILIC LEUKEMIA, CHRONIC.
The initial phase of chronic myeloid leukemia consisting of an relatively indolent period lasting from 4 to 7 years. Patients range from asymptomatic to those exhibiting ANEMIA; SPLENOMEGALY; and increased cell turnover. There are 5% or fewer blast cells in the blood and bone marrow in this phase.
The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.
Disease having a short and relatively severe course.
Therapeutic act or process that initiates a response to a complete or partial remission level.
A leukemia/lymphoma found predominately in children and adolescents and characterized by a high number of lymphoblasts and solid tumor lesions. Frequent sites involve LYMPH NODES, skin, and bones. It most commonly presents as leukemia.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
A rare, aggressive variant of MULTIPLE MYELOMA characterized by the circulation of excessive PLASMA CELLS in the peripheral blood. It can be a primary manifestation of multiple myeloma or develop as a terminal complication during the disease.
The phase of chronic myeloid leukemia following the chronic phase (LEUKEMIA, MYELOID, CHRONIC-PHASE), where there are increased systemic symptoms, worsening cytopenias, and refractory LEUKOCYTOSIS.
Mapping of the KARYOTYPE of a cell.
A lymphoid leukemia characterized by a profound LYMPHOCYTOSIS with or without LYMPHADENOPATHY, hepatosplenomegaly, frequently rapid progression, and short survival. It was formerly called T-cell chronic lymphocytic leukemia.
A strain of PRIMATE T-LYMPHOTROPIC VIRUS 1 isolated from mature T4 cells in patients with T-lymphoproliferation malignancies. It causes adult T-cell leukemia (LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED), T-cell lymphoma (LYMPHOMA, T-CELL), and is involved in mycosis fungoides, SEZARY SYNDROME and tropical spastic paraparesis (PARAPARESIS, TROPICAL SPASTIC).
Established cell cultures that have the potential to propagate indefinitely.
A chronic leukemia characterized by a large number of circulating prolymphocytes. It can arise spontaneously or as a consequence of transformation of CHRONIC LYMPHOCYTIC LEUKEMIA.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
A transcription factor that dimerizes with the cofactor CORE BINDING FACTOR BETA SUBUNIT to form core binding factor. It contains a highly conserved DNA-binding domain known as the runt domain. Runx1 is frequently mutated in human LEUKEMIAS.
A leukemia affecting young children characterized by SPLENOMEGALY, enlarged lymph nodes, rashes, and hemorrhages. Traditionally classed as a myeloproliferative disease, it is now considered a mixed myeloproliferative-mylelodysplastic disorder.
A leukemia/lymphoma found predominately in children and young adults and characterized LYMPHADENOPATHY and THYMUS GLAND involvement. It most frequently presents as a lymphoma, but a leukemic progression in the bone marrow is common.
A rare acute myeloid leukemia in which the primary differentiation is to BASOPHILS. It is characterized by an extreme increase of immature basophilic granulated cells in the bone marrow and blood. Mature basophils are usually sparse.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
A pathologic change in leukemia in which leukemic cells permeate various organs at any stage of the disease. All types of leukemia show various degrees of infiltration, depending upon the type of leukemia. The degree of infiltration may vary from site to site. The liver and spleen are common sites of infiltration, the greatest appearing in myelocytic leukemia, but infiltration is seen also in the granulocytic and lymphocytic types. The kidney is also a common site and of the gastrointestinal system, the stomach and ileum are commonly involved. In lymphocytic leukemia the skin is often infiltrated. The central nervous system too is a common site.
A hydrolase enzyme that converts L-asparagine and water to L-aspartate and NH3. EC
A receptor tyrosine kinase that is involved in HEMATOPOIESIS. It is closely related to FMS PROTO-ONCOGENE PROTEIN and is commonly mutated in acute MYELOID LEUKEMIA.
An aberrant form of human CHROMOSOME 22 characterized by translocation of the distal end of chromosome 9 from 9q34, to the long arm of chromosome 22 at 22q11. It is present in the bone marrow cells of 80 to 90 per cent of patients with chronic myelocytic leukemia (LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE).
A general term for various neoplastic diseases of the lymphoid tissue.
A myelodysplastic/myeloproliferative disorder characterized by myelodysplasia associated with bone marrow and peripheral blood patterns similar to CHRONIC MYELOID LEUKEMIA, but cytogenetically lacking a PHILADELPHIA CHROMOSOME or bcr/abl fusion gene (GENES, ABL).
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.
Immunological rejection of leukemia cells following bone marrow transplantation.
A replication-defective strain of Murine leukemia virus (LEUKEMIA VIRUS, MURINE) capable of transforming lymphoid cells and producing a rapidly progressing lymphoid leukemia after superinfection with FRIEND MURINE LEUKEMIA VIRUS; MOLONEY MURINE LEUKEMIA VIRUS; or RAUSCHER VIRUS.
Abnormal number or structure of chromosomes. Chromosome aberrations may result in CHROMOSOME DISORDERS.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
A receptor subunit that combines with CYTOKINE RECEPTOR GP130 to form the dual specificity receptor for LEUKEMIA INHIBITORY FACTOR and ONCOSTATIN M. The subunit is also a component of the CILIARY NEUROTROPHIC FACTOR RECEPTOR. Both membrane-bound and secreted isoforms of the receptor subunit exist due to ALTERNATIVE SPLICING of its mRNA. The secreted isoform is believed to act as an inhibitory receptor, while the membrane-bound form is a signaling receptor.
Conditions in which the abnormalities in the peripheral blood or bone marrow represent the early manifestations of acute leukemia, but in which the changes are not of sufficient magnitude or specificity to permit a diagnosis of acute leukemia by the usual clinical criteria.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
Process of classifying cells of the immune system based on structural and functional differences. The process is commonly used to analyze and sort T-lymphocytes into subsets based on CD antigens by the technique of flow cytometry.
Remnant of a tumor or cancer after primary, potentially curative therapy. (Dr. Daniel Masys, written communication)
The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.
A spectrum of disorders characterized by clonal expansions of the peripheral blood LYMPHOCYTE populations known as large granular lymphocytes which contain abundant cytoplasm and azurophilic granules. Subtypes develop from either CD3-negative NATURAL KILLER CELLS or CD3-positive T-CELLS. The clinical course of both subtypes can vary from spontaneous regression to progressive, malignant disease.
Examination of CHROMOSOMES to diagnose, classify, screen for, or manage genetic diseases and abnormalities. Following preparation of the sample, KARYOTYPING is performed and/or the specific chromosomes are analyzed.
Family of RNA viruses that infects birds and mammals and encodes the enzyme reverse transcriptase. The family contains seven genera: DELTARETROVIRUS; LENTIVIRUS; RETROVIRUSES TYPE B, MAMMALIAN; ALPHARETROVIRUS; GAMMARETROVIRUS; RETROVIRUSES TYPE D; and SPUMAVIRUS. A key feature of retrovirus biology is the synthesis of a DNA copy of the genome which is integrated into cellular DNA. After integration it is sometimes not expressed but maintained in a latent state (PROVIRUSES).
Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
The return of a sign, symptom, or disease after a remission.
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
Highly proliferative, self-renewing, and colony-forming stem cells which give rise to NEOPLASMS.
Virus diseases caused by the RETROVIRIDAE.
Progenitor cells from which all blood cells derive.
A cell line derived from cultured tumor cells.
Binary compounds of oxygen containing the anion O(2-). The anion combines with metals to form alkaline oxides and non-metals to form acidic oxides.
Transcriptional trans-acting proteins of the promoter elements found in the long terminal repeats (LTR) of HUMAN T-LYMPHOTROPIC VIRUS 1 and HUMAN T-LYMPHOTROPIC VIRUS 2. The tax (trans-activator x; x is undefined) proteins act by binding to enhancer elements in the LTR.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
Inorganic or organic compounds that contain arsenic.
The ordered rearrangement of gene regions by DNA recombination such as that which occurs normally during development.
An orally administered anthracycline antineoplastic. The compound has shown activity against BREAST NEOPLASMS; LYMPHOMA; and LEUKEMIA.
A nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus.
A species of GAMMARETROVIRUS causing leukemia in the gibbon ape. Natural transmission is by contact.
DNA present in neoplastic tissue.
A specific pair of GROUP G CHROMOSOMES of the human chromosome classification.
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.
An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE).
Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation.
A member of the myeloid leukemia factor (MLF) protein family with multiple alternatively spliced transcript variants encoding different protein isoforms. In hematopoietic cells, it is located mainly in the nucleus, and in non-hematopoietic cells, primarily in the cytoplasm with a punctate nuclear localization. MLF1 plays a role in cell cycle differentiation.
Retrovirus-associated DNA sequences (abl) originally isolated from the Abelson murine leukemia virus (Ab-MuLV). The proto-oncogene abl (c-abl) codes for a protein that is a member of the tyrosine kinase family. The human c-abl gene is located at 9q34.1 on the long arm of chromosome 9. It is activated by translocation to bcr on chromosome 22 in chronic myelogenous leukemia.
Endogenous substances, usually proteins, which are effective in the initiation, stimulation, or termination of the genetic transcription process.
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals.
A neoplastic disease of cats frequently associated with feline leukemia virus infection.
A subdiscipline of genetics which deals with the cytological and molecular analysis of the CHROMOSOMES, and location of the GENES on chromosomes, and the movements of chromosomes during the CELL CYCLE.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity.
An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia.
A specific pair of GROUP C CHROMOSOMES of the human chromosome classification.
Endogenous or exogenous substances which inhibit the normal growth of human and animal cells or micro-organisms, as distinguished from those affecting plant growth (= PLANT GROWTH REGULATORS).
A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative.
Normal cellular genes homologous to viral oncogenes. The products of proto-oncogenes are important regulators of biological processes and appear to be involved in the events that serve to maintain the ordered procession through the cell cycle. Proto-oncogenes have names of the form c-onc.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.
In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships.
Proteins which bind to DNA. The family includes proteins which bind to both double- and single-stranded DNA and also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases.
Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
A lymphoid neoplastic disease in cattle caused by the bovine leukemia virus. Enzootic bovine leukosis may take the form of lymphosarcoma, malignant lymphoma, or leukemia but the presence of malignant cells in the blood is not a consistent finding.
An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
Antibodies produced by a single clone of cells.
RNA present in neoplastic tissue.
An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.
Elements of limited time intervals, contributing to particular results or situations.
Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation.
The short, acrocentric human chromosomes, called group G in the human chromosome classification. This group consists of chromosome pairs 21 and 22 and the Y chromosome.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)
A form of systemic mastocytosis (MASTOCYTOSIS, SYSTEMIC) characterized by the presence of large numbers of tissue MAST CELLS in the peripheral blood without skin lesions. It is a high-grade LEUKEMIA disease with bone marrow smear of >20% MAST CELLS, multi-organ failure and a short survival.
The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.
A group of genetically identical cells all descended from a single common ancestral cell by mitosis in eukaryotes or by binary fission in prokaryotes. Clone cells also include populations of recombinant DNA molecules all carrying the same inserted sequence. (From King & Stansfield, Dictionary of Genetics, 4th ed)
Proteins found in the nucleus of a cell. Do not confuse with NUCLEOPROTEINS which are proteins conjugated with nucleic acids, that are not necessarily present in the nucleus.
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.
Cell surface receptors formed from the dimerization of LIF RECEPTOR ALPHA SUBUNIT with CYTOKINE RECEPTOR GP130. Although originally described as receptors for LEUKEMIA INHIBITORY FACTOR these receptors also bind the closely-related protein ONCOSTATIN M and are referred to as both LIF receptors and type I oncostatin M receptors.
A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.
A strain of Murine leukemia virus (LEUKEMIA VIRUS, MURINE) isolated from radiation-induced lymphomas in C57BL mice. It is leukemogenic, thymotrophic, can be transmitted vertically, and replicates only in vivo.
A 67-kDa sialic acid binding lectin that is specific for MYELOID CELLS and MONOCYTE-MACROPHAGE PRECURSOR CELLS. This protein is the smallest siglec subtype and contains a single immunoglobulin C2-set domain. It may play a role in intracellular signaling via its interaction with SHP-1 PROTEIN-TYROSINE PHOSPHATASE and SHP-2 PROTEIN-TYROSINE PHOSPHATASE.
A rare myeloproliferative disorder that is characterized by a sustained, mature neutrophilic leukocytosis. No monocytosis, EOSINOPHILIA, or basophilia is present, nor is there a PHILADELPHIA CHROMOSOME or bcr-abl fusion gene (GENES, ABL).
White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS.
Mice homozygous for the mutant autosomal recessive gene "scid" which is located on the centromeric end of chromosome 16. These mice lack mature, functional lymphocytes and are thus highly susceptible to lethal opportunistic infections if not chronically treated with antibiotics. The lack of B- and T-cell immunity resembles severe combined immunodeficiency (SCID) syndrome in human infants. SCID mice are useful as animal models since they are receptive to implantation of a human immune system producing SCID-human (SCID-hu) hematochimeric mice.
An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.
Agents that inhibit PROTEIN KINASES.
Duplex DNA sequences in eukaryotic chromosomes, corresponding to the genome of a virus, that are transmitted from one cell generation to the next without causing lysis of the host. Proviruses are often associated with neoplastic cell transformation and are key features of retrovirus biology.
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.
Leukocytes with abundant granules in the cytoplasm. They are divided into three groups according to the staining properties of the granules: neutrophilic, eosinophilic, and basophilic. Mature granulocytes are the NEUTROPHILS; EOSINOPHILS; and BASOPHILS.
The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.
A type of IN SITU HYBRIDIZATION in which target sequences are stained with fluorescent dye so their location and size can be determined using fluorescence microscopy. This staining is sufficiently distinct that the hybridization signal can be seen both in metaphase spreads and in interphase nuclei.
Antimetabolites that are useful in cancer chemotherapy.
A specific pair of GROUP C CHROMOSOMES of the human chromosome classification.
A potent inhibitor of ADENOSINE DEAMINASE. The drug induces APOPTOSIS of LYMPHOCYTES, and is used in the treatment of many lymphoproliferative malignancies, particularly HAIRY CELL LEUKEMIA. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.
A genus in the family RETROVIRIDAE consisting of exogenous horizontally-transmitted viruses found in a few groups of mammals. Infections caused by these viruses include human B- or adult T-cell leukemia/lymphoma (LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED), and bovine leukemia (ENZOOTIC BOVINE LEUKOSIS). The type species is LEUKEMIA VIRUS, BOVINE.
A CELL LINE derived from human T-CELL LEUKEMIA and used to determine the mechanism of differential susceptibility to anti-cancer drugs and radiation.
Deoxyribonucleic acid that makes up the genetic material of viruses.
All of the processes involved in increasing CELL NUMBER including CELL DIVISION.
The biosynthesis of RNA carried out on a template of DNA. The biosynthesis of DNA from an RNA template is called REVERSE TRANSCRIPTION.
Membrane proteins encoded by the BCL-2 GENES and serving as potent inhibitors of cell death by APOPTOSIS. The proteins are found on mitochondrial, microsomal, and NUCLEAR MEMBRANE sites within many cell types. Overexpression of bcl-2 proteins, due to a translocation of the gene, is associated with follicular lymphoma.
The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells.
Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals.
Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms.
The relationship between the dose of an administered drug and the response of the organism to the drug.
The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.
The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES.
Glycoproteins found on immature hematopoietic cells and endothelial cells. They are the only molecules to date whose expression within the blood system is restricted to a small number of progenitor cells in the bone marrow.
Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
A neoplasm of prolymphocytes affecting the blood, bone marrow, and spleen. It is characterized by prolymphocytes exceeding 55% of the lymphoid cells in the blood and profound splenomegaly.
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
A method (first developed by E.M. Southern) for detection of DNA that has been electrophoretically separated and immobilized by blotting on nitrocellulose or other type of paper or nylon membrane followed by hybridization with labeled NUCLEIC ACID PROBES.
Genes whose gain-of-function alterations lead to NEOPLASTIC CELL TRANSFORMATION. They include, for example, genes for activators or stimulators of CELL PROLIFERATION such as growth factors, growth factor receptors, protein kinases, signal transducers, nuclear phosphoproteins, and transcription factors. A prefix of "v-" before oncogene symbols indicates oncogenes captured and transmitted by RETROVIRUSES; the prefix "c-" before the gene symbol of an oncogene indicates it is the cellular homolog (PROTO-ONCOGENES) of a v-oncogene.
Infections caused by the HTLV or BLV deltaretroviruses. They include human T-cell leukemia-lymphoma (LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED).
Antigens on surfaces of cells, including infectious or foreign cells or viruses. They are usually protein-containing groups on cell membranes or walls and may be isolated.
The development and formation of various types of BLOOD CELLS. Hematopoiesis can take place in the BONE MARROW (medullary) or outside the bone marrow (HEMATOPOIESIS, EXTRAMEDULLARY).
A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.
A specific pair of GROUP E CHROMOSOMES of the human chromosome classification.
Protein kinases that catalyze the PHOSPHORYLATION of TYROSINE residues in proteins with ATP or other nucleotides as phosphate donors.
The action of a drug in promoting or enhancing the effectiveness of another drug.
The largest of polypeptide chains comprising immunoglobulins. They contain 450 to 600 amino acid residues per chain, and have molecular weights of 51-72 kDa.
The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment.
A specific pair of GROUP C CHROMOSOMES of the human chromosome classification.
Experimental transplantation of neoplasms in laboratory animals for research purposes.
Clinical conditions caused by an abnormal chromosome constitution in which there is extra or missing chromosome material (either a whole chromosome or a chromosome segment). (from Thompson et al., Genetics in Medicine, 5th ed, p429)
Nucleosides containing arabinose as their sugar moiety.
An anthracenedione-derived antineoplastic agent.
A genus of RETROVIRIDAE comprising endogenous sequences in mammals, related RETICULOENDOTHELIOSIS VIRUSES, AVIAN, and a reptilian virus. Many species contain oncogenes and cause leukemias and sarcomas.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
The functional hereditary units of VIRUSES.
Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation.
The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE.
Proto-oncogene protein bcr is a serine-threonine kinase that functions as a negative regulator of CELL PROLIFERATION and NEOPLASTIC CELL TRANSFORMATION. It is commonly fused with cellular abl protein to form BCR-ABL FUSION PROTEINS in PHILADELPHIA CHROMOSOME positive LEUKEMIA patients.
An inheritable change in cells manifested by changes in cell division and growth and alterations in cell surface properties. It is induced by infection with a transforming virus.
The determination of the pattern of genes expressed at the level of GENETIC TRANSCRIPTION, under specific circumstances or in a specific cell.
A bifunctional enzyme that catalyzes the synthesis and HYDROLYSIS of CYCLIC ADP-RIBOSE (cADPR) from NAD+ to ADP-RIBOSE. It is a cell surface molecule which is predominantly expressed on LYMPHOID CELLS and MYELOID CELLS.
Proteins that are normally involved in holding cellular growth in check. Deficiencies or abnormalities in these proteins may lead to unregulated cell growth and tumor development.
Differentiation antigens expressed on B-lymphocytes and B-cell precursors. They are involved in regulation of B-cell proliferation.
The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION.
Tetracyclic spiro-BENZAZEPINES isolated from the seeds of CEPHALOTAXUS. They are esters of the alkaloid cephalotaxine and may be effective as antineoplastic agents.
An enzyme that synthesizes DNA on an RNA template. It is encoded by the pol gene of retroviruses and by certain retrovirus-like elements. EC
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
A cytologic technique for measuring the functional capacity of tumor stem cells by assaying their activity. It is used primarily for the in vitro testing of antineoplastic agents.
Infections produced by oncogenic viruses. The infections caused by DNA viruses are less numerous but more diverse than those caused by the RNA oncogenic viruses.
Immunoglobulins induced by antigens specific for tumors other than the normally occurring HISTOCOMPATIBILITY ANTIGENS.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.

p53 status of newly established acute myeloid leukaemia cell lines. (1/5352)

We analysed the status of the p53 gene and protein in eight newly established acute myeloid leukaemia (AML) cell lines representing blast cells of either de novo leukaemia patients in first remission or patients with relapsed and chemotherapy-resistant disease causing their death. There were no mutations in the p53 gene in any of the cell lines as analysed by single-strand conformation polymorphism of amplified exons 5-8. However, the p53 protein was clearly and consistently expressed in all of these cell lines, as shown by immunohistochemistry, Western blotting and flow cytometry. The consistently expressed p53 protein was located in both the nucleus and the cytoplasm of all the cell lines and, as shown by flow cytometry, it was mostly in a conformation typical of the mutated protein. These AML cell lines offer a tool for studying the production and function of the p53 protein and its possible role in cell cycle regulation and chemoresistance as well as in the regulation of apoptosis in AML.  (+info)

Patterns of care and survival for adolescents and young adults with acute leukaemia--a population-based study. (2/5352)

We report a population-based study of patterns of care and survival for people with acute leukaemia diagnosed at age 15-29 years during 1984-94 in regions of England and Wales covered by specialist leukaemia registries. There were 879 patients: 417 with acute lymphoblastic leukaemia (ALL) and 462 with acute myeloid leukaemia (AML). For ALL, actuarial survival rates were 43% at 5 years after diagnosis and 37% at 10 years. Survival improved significantly between 1984-88 and 1989-94 for those aged 15-19 at diagnosis. Patients entered in national clinical trials and those not entered had similar survival rates. Survival rates were similar at teaching and non-teaching hospitals and at hospitals treating different numbers of study patients per year. For AML, survival rates were 42% at 5 years after diagnosis and 39% at 10 years. Survival improved significantly between 1984-88 and 1989-94. Patients entered in the Medical Research Council AML10 trial had a higher survival rate than those who were in the earlier AML9 trial. Survival did not vary with category of hospital. We conclude that survival has improved for adolescents and young adults with acute leukaemia but that there is at present no evidence that centralized treatment results in a survival benefit for patients in this age group.  (+info)

Toward a leukemia treatment strategy based on the probability of stem cell death: an essay in honor of Dr. Emil J Freireich. (3/5352)

Dr. Emil J Freireich is a pioneer in the rational treatment of cancer in general and leukemia in particular. This essay in his honor suggests that the cell kill concept of chemotherapy of acute myeloblastic leukemia be extended to include two additional ideas. The first concept is that leukemic blasts, like normal hemopoietic cells, are organized in hierarchies, headed by stem cells. In both normal and leukemic hemopoiesis, killing stem cells will destroy the system; furthermore, both normal and leukemic cells respond to regulators. It follows that acute myelogenous leukemia should be considered as a dependent neoplasm. The second concept is that cell/drug interaction should be considered as two phases. The first, or proximal phase, consists of the events that lead up to injury; the second, or distal phase, comprises the responses of the cell that contribute to either progression to apoptosis or recovery. Distal responses are described briefly. Regulated drug sensitivity is presented as an example of how distal responses might be used to improve treatment.  (+info)

Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias. (4/5352)

The AML1 gene encoding the DNA-binding alpha-subunit in the Runt domain family of heterodimeric transcription factors has been noted for its frequent involvement in chromosomal translocations associated with leukemia. Using reverse transcriptase-polymerase chain reaction (RT-PCR) combined with nonisotopic RNase cleavage assay (NIRCA), we found point mutations of the AML1 gene in 8 of 160 leukemia patients: silent mutations, heterozygous missense mutations, and biallelic nonsense or frameshift mutations in 2, 4, and 2 cases, respectively. The mutations were all clustered within the Runt domain. Missense mutations identified in 3 patients showed neither DNA binding nor transactivation, although being active in heterodimerization. These defective missense mutants may be relevant to the predisposition or progression of leukemia. On the other hand, the biallelic nonsense mutants encoding truncated AML1 proteins lost almost all functions examined and may play a role in leukemogenesis leading to acute myeloblastic leukemia.  (+info)

Cyclin A1 expression in leukemia and normal hematopoietic cells. (5/5352)

Human cyclin A1 is a newly cloned, tissue-specific cyclin that is prominently expressed in normal testis. In this study, we showed that cyclin A1 was highly expressed in a subset of leukemia samples from patients. The highest frequency of cyclin A1 overexpression was observed in acute myelocytic leukemias, especially those that were at the promyelocyte (M3) and myeloblast (M2) stages of development. Cyclin A1 expression was also detected in normal CD34(+) progenitor cells. The expression of cyclin A1 increased when these cells were stimulated to undergo myeloid differentiation in vitro. Taken together, our observations suggest that cyclin A1 may have a role in hematopoiesis. High levels of cyclin A1 expression are especially associated with certain leukemias blocked at the myeloblast and promyelocyte stages of differentiation.  (+info)

Pneumonia in febrile neutropenic patients and in bone marrow and blood stem-cell transplant recipients: use of high-resolution computed tomography. (6/5352)

PURPOSE: To obtain statistical data on the use of high-resolution computed tomography (HRCT) for early detection of pneumonia in febrile neutropenic patients with unknown focus of infection. MATERIALS AND METHODS: One hundred eighty-eight HRCT studies were performed prospectively in 112 neutropenic patients with fever of unknown origin persisting for more than 48 hours despite empiric antibiotic treatment. Fifty-four of these studies were performed in transplant recipients. All patients had normal chest roentgenograms. If pneumonia was detected by HRCT, guided bronchoalveolar lavage was recommended. Evidence of pneumonia on chest roentgenograms during follow-up and micro-organisms detected during follow-up were regarded as documentation of pneumonia. RESULTS: Of the 188 HRCT studies, 112 (60%) showed pneumonia and 76 were normal. Documentation of pneumonia was possible in 61 cases by chest roentgenography or micro-organism detection (54%) (P < 10(-6)). Sensitivity of HRCT was 87% (88% in transplant recipients), specificity was 57% (67%), and the negative predictive value was 88% (97%). A time gain of 5 days was achieved by the additional use of HRCT compared to an exclusive use of chest roentgenography. CONCLUSION: The high frequency of inflammatory pulmonary disease after a suspicious HRCT scan (> 50%) proves that pneumonia is not excluded by a normal chest roentgenogram. Given the significantly longer duration of febrile episodes in transplant recipients, HRCT findings are particularly relevant in this subgroup. Patients with normal HRCT scans, particularly transplant recipients, have a low risk of pneumonia during follow-up. All neutropenic patients with fever of unknown origin and normal chest roentgenograms should undergo HRCT.  (+info)

A novel ubiquitin-specific protease, UBP43, cloned from leukemia fusion protein AML1-ETO-expressing mice, functions in hematopoietic cell differentiation. (7/5352)

Using PCR-coupled subtractive screening-representational difference analysis, we have cloned a novel gene from AML1-ETO knockin mice. This gene is highly expressed in the yolk sac and fetal liver of the knockin mice. Nucleotide sequence analysis indicates that its cDNA contains an 1,107-bp open reading frame encoding a 368-amino-acid polypeptide. Further protein sequence and protein translation analysis shows that it belongs to a family of ubiquitin-specific proteases (UBP), and its molecular mass is 43 kDa. Therefore, we have named this gene UBP43. Like other ubiquitin proteases, the UBP43 protein has deubiquitinating enzyme activity. Protein ubiquitination has been implicated in many important cellular events. In wild-type adult mice, UBP43 is highly expressed in the thymus and in peritoneal macrophages. Among nine different murine hematopoietic cell lines analyzed, UBP43 expression is detectable only in cell lines related to the monocytic lineage. Furthermore, its expression is regulated during cytokine-induced monocytic cell differentiation. We have investigated its function in the hematopoietic myeloid cell line M1. UBP43 was introduced into M1 cells by retroviral gene transfer, and several high-expressing UBP43 clones were obtained for further study. Morphologic and cell surface marker examination of UBP43/M1 cells reveals that overexpression of UBP43 blocks cytokine-induced terminal differentiation of monocytic cells. These data suggest that UBP43 plays an important role in hematopoiesis by modulating either the ubiquitin-dependent proteolytic pathway or the ubiquitination state of another regulatory factor(s) during myeloid cell differentiation.  (+info)

Autologous blood stem cell transplantation for acute myeloblastic leukemia in first complete remission. Intensification therapy before transplantation does not prolong disease-free survival. (8/5352)

BACKGROUND AND OBJECTIVE: To compare the clinical results of two consecutive therapeutic protocols including autologous blood stem cell transplantation (ABSCT) for patients with de novo acute myeloblastic leukemia (AML) in first complete remission (CR1). DESIGN AND METHODS: Between November 1989 and January 1997, 50 patients with AML in CR1 underwent ABSCT using two consecutive protocols. In the first one (Group A, 25 patients) peripheral blood stem cells (PBSC) were collected after induction and consolidation chemotherapy courses, and ABSCT was performed immediately thereafter. In the subsequent 25 patients (Group B), PBSC were collected after consolidation alone, and a further chemotherapy course with intermediate dose cytarabine (Ara-C 1 g/m2/12 h x3 days) and mitoxantrone (12 mg/m2/d x3 days) was administered as early intensification. The conditioning regimen consisted of busulfan (16 mg/kg) and cyclophosphamide (200 mg/kg) in every case. RESULTS: Hematopoietic engraftment was slightly quicker in Group B, with median times to reach 0.5 x 10(9) neutrophils/L and 20 x 10(9) platelets/L being 13 and 12 days in Group A and 12 and 11 days in Group B, respectively. There were three graft failures (8%) (2 in Group A and 1 in Group B) and three transplant-related deaths (8%) (2 in Group A and 1 in Group B). No significant differences were observed between the groups in terms of relapse (64% at 4-years in Group A and 81% in Group B). Likewise, the actuarial 4-year disease-free survival (DFS) was not significantly different between the two groups (32% v 18%). INTERPRETATION AND CONCLUSIONS: Our study confirms that AML patients in CR1 receiving ABSCT have rapid engraftment with low mortality. However, autologous transplants with PBSC collected after consolidation chemotherapy were still associated with a high rate of relapse (RR). This RR was not apparently reduced by the administration of intermediate dose Ara-C before transplantation.  (+info)

Also known as: Acute myelocytic leukemia / Acute myeloid leukemia / Leukemia, Myeloid, Acute / Acute myelocytic leukaemia / Acute myeloblastic leukemia with failed remission / Leukaemia myeloblastic acute / AML / Non-lymphoblastic leukaemia acute / Non-lymphoblastic leukemia acute / Acute myeloid leukemia NOS / Myeloid leukaemia, acute / Leukaemias acute myeloid / Acute myeloblastic leukemia / Acute myeloblastic leukaemia / Leukemia myeloblastic acute / Acute granulocytic leukaemia / Acute granulocytic leukemia / Acute myeloid leukaemia / Myeloid leukemia, acute / Acute myeloid leukaemia NOS ...
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2015 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2015 Summary Global Markets - Market research report and industry analysis - 9304064
DORLHIAC-LLACER, P.E. et al. In vitro cytotoxicity of the LDE: daunorubicin complex in acute myelogenous leukemia blast cells. Braz J Med Biol Res [online]. 2001, vol.34, n.10, pp.1257-1263. ISSN 1414-431X. http://dx.doi.org/10.1590/S0100-879X2001001000004.. Acute myelogenous leukemia (AML) blast cells show high-affinity degradation of low-density lipoprotein (LDL), suggesting an increased expression of cellular LDL receptors. LDE is a lipid microemulsion easily synthesized in vitro which is known to mimic the metabolic pathway of LDL. We used LDE as a carrier for daunorubicin and assayed the cytotoxicity of the complex using AML blast cells since RT-PCR analysis showed that AML cells express LDL receptor mRNA. The LDE:daunorubicin complex killed 46.7% of blast cells and 20.2% of normal bone marrow cells (P,0.001; Student t-test). Moreover, this complex destroyed AML blast cells as efficiently as free daunorubicin. Thus, LDE might be a suitable carrier of chemotherapeutic agents targeting these ...
Looking for information on Acute myelocytic leukemia? Medigest has all you need to know about Acute myelocytic leukemia - Symptoms and Signs, Causes, Treatments and definition
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2017 Size and Share Published in 2017-06-30 Available for US$ 2500 at Researchmoz.us
The published literature suggests that less than 25% of patients with de novo acute myeloblastic leukaemia (AML), treated by intensive chemotherapy, are cured by this approach [1, 2]. Modest...
Acute myelogenous leukemia is a very aggressive form of cancer and individuals diagnosed with the condition will need to begin medical treatment right away to avoid serious complications. Acute myelogenous leukemia is considered the most common type of leukemia in the country and responds well to treatment in the majority of cases. The goal of treatment is to bring the condition into remission for a long-term or permanent basis. There are several different treatments available for acute myelogenous leukemia and each one may be used in conjunction with others to ensure the best course of treatment for the individual affected.. The first step in the treatment of acute myelogenous leukemia is obtaining a positive diagnosis of the condition. There are several conditions that may mimic the symptoms of acute myelogenous leukemia and, since acute myelogenous leukemia is only one of many types of leukemia, the exact cause of the appearance of symptoms must be discovered in order to be able to treat the ...
ReportsnReports added a new report on The Acute Myelocytic Leukemia Market report that delivers the clean elaborated structure of the Report comprising each and every business-related information of the market at a global level. The in-depth study on the current state which focuses on the major drivers and restraint...
Activating mutations of the FMS-like tyrosine kinase 3 gene (FLT3) occur in approximately one-third of patients with acute myeloid leukaemia (AML) and predict for a poor outcome. Heat shock protein 90 (Hsp90) is a molecular chaperone that is frequently used by cancer cells to stabilise mutant oncoproteins. Mutant FLT3 is chaperoned by Hsp90 in primary AML blasts whereas unmutated FLT3 is not, making Hsp90 inhibitors potentially useful therapeutically. The present study showed that inhibition of Hsp90 by 17- allylamino-17-demethoxygeldanamycin (17-AAG) was cytotoxic to primary AML cells expressing mutant FLT3. Inhibition of Hsp90 results in altered downstream signalling effects in primary AML cells with disruption of Janus kinase-signal transducer and activator of transcription (JAK-STAT), mitogen-activated protein kinase and phosphatidylinositol 3/AKT signalling pathways. Co-treatment of blasts with 17-AAG and cytarabine resulted in a synergistic or additive effect in approximately 50% of AML ...
Free Online Library: Post-remission therapy of adult acute myeloid leukemia: high dose cytosine-arabinoside versus other consolidation regimens/Konsolidaciona terapija akutne mijeloidne leukemije: visoke doze citozinarabinozida naspram drugih konsolidacionih rezima sa citozin-arabinozidom.(Original study/Originalni naucni rad, Report) by Medicinski Pregled; Health, general Science and technology, general Acute myelocytic leukemia Drug therapy Research Cancer regression Cytarabine Health aspects
CEBPA mutations in patients with de novo acute myeloid leukemia: data analysis in a Chinese population Long Su, SuJun Gao, XiaoLiang Liu, YeHui Tan, Lu Wang, Wei Li Cancer Center, The First Hospital, Jilin University, Changchun, Peoples Republic of China Background: This study was aimed to explore the clinical characteristics and prognoses of acute myeloid leukemia (AML) patients with CEBPA mutations. Patients and methods: Three hundred and forty-five patients with de novo AML were retrospectively analyzed with regard to CEBPA mutations, clinical characteristics, therapeutic responses, and long-term outcomes. Results: CEBPA mutations were detected in 59 patients (17.10%), with 47 cases harboring double mutations and 12 cases harboring single mutations. In those with a normal karyotype (NK), 44 cases (25.29%) were detected with CEBPA mutations. The following characteristics were observed in CEBPA-mutated patients: most (66.10%) of them were M1 or M2; they presented with higher peripheral white blood
M2 is a subtype of AML (Acute Myeloid Leukemia). It is also known as Acute Myeloblastic Leukemia with Maturation. Acute myeloid leukemia (AML) is a type of cancer affecting blood cells that eventually develop into non-lymphocyte white blood cells. The disease originates from the bone marrow, the soft inner portion of select bones where blood stem cells develop into either lymphocyte or in this particular condition, myeloid cells. This acute disease prevents bone marrow cells from properly maturing, thus causing an accumulation of immature myeloblast cells in the bone marrow. Acute myeloid leukemia is more lethal than chronic myeloid leukemia, a disease that affects the same myeloid cells, but at a different pace. Many of the immature blast cells in acute myeloid leukemia have a higher loss of function and thus, a higher inability to carry out normal functions than those more developed immature myeloblast cells in chronic myeloid leukemia (ODonnell et al. 2012). Acute in acute myeloid leukemia ...
Pain management information for pain medicine healthcare professionals in treating and caring for their patients. Clinical Pain Advisor offers news, case studies and more.
Synonyms for Acute myeloid leukaemia in Free Thesaurus. Antonyms for Acute myeloid leukaemia. 1 synonym for acute myeloid leukemia: acute myelocytic leukemia. What are synonyms for Acute myeloid leukaemia?
BACKGROUND AND OBJECTIVE: Tumor necrosis factor-a plays an important role in hematopoiesis. Its effects are mediated through two membrane-bound receptors: TNF-R I (p55; CD 120a) and TNF-R II (p75; CD 120b). The aim of our study was to investigate the relative roles of these receptors. DESIGN AND METHODS: We analyzed in 16 acute myeloid leukemia cases whether TNF-alpha could induce in vitro maturation and apoptosis. We then investigated which of the two receptors was provoking monocytic maturation and which was responsible for apoptosis by using the agonistic MoAb HTR-9, directed at CD120a, and the CD120b antagonistic MoAb UTR-1. RESULTS: Monocytic maturation (morphologic and immunologic) was induced in all cases studied, although to different rates, by TNF-alpha and by HTR-9 incubation. The addition of UTR-1 to TNF-alpha did not abolish maturation, nor did it affect apoptosis, which was present in primary AML cultures after 4 and 10 days. INTERPRETATION AND CONCLUSIONS: We present here evidence ...
Define Acute myeloid leukaemia. Acute myeloid leukaemia synonyms, Acute myeloid leukaemia pronunciation, Acute myeloid leukaemia translation, English dictionary definition of Acute myeloid leukaemia. Noun 1. acute myeloid leukemia - acute leukemia characterized by proliferation of granular leukocytes; most common in adolescents and young adults acute...
1. Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U. et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99:4326-35 2. Whitman SP, Archer KJ, Feng L, Baldus C, Becknell B, Carlson BD. et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res. 2001;61:7233-39 3. Mizuki M, Fenski R, Halfter H, Matsumura I, Schmidt R, Muller C. et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood. 2000;96:3907-14 4. Brandts CH, Sargin B, Rode M, Biermann C, Lindtner B, Schwable J. et al. Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and ...
Disease relapse is the most common cause of death after allogeneic stem cell transplantation for acute myeloid leukemia. Patients at high risk for relapse may benefit from a novel, biologically rational therapeutic intervention to prevent this outcome. PF-04449913 is a small molecule inhibitor of the hedgehog (Hh) pathway that inhibits the protein Smoothened (SMO). Aberrant Hh signaling may contribute to the survival and expansion of the leukemia stem cell, and inhibiting the Hh pathway can eliminate these cells. Therefore, targeting Hh may be a logical intervention in the post-transplantation setting for those with high risk of relapse. The investigators propose a phase 2 study of PF-04449913 in patients with acute myeloid leukemia who have received an allogeneic stem cell transplantation and are at high risk of relapse.. This is an open label, phase 2 study employing PF-04449913 in acute myeloid leukemia patients who received an allogeneic stem cell transplantation and are at high risk of ...
Acute myeloid leukemia is also called acute myelocytic leukemia, acute myelogenous leukemia, acute granulocytic leukemia, acute non-lymphocytic leukemia, or sometimes just AML. It is most common in older people.
OBJECTIVE: To elucidate the regulatory effect of microRNA-34b on the occurrence of pediatric acute myeloid leukemia and the underlying mechanism. PATIENTS
This is a prospective, non-therapeutic study, assessing the significance of minimal residual disease (MRD) at three different time points in relation to allogeneic HCT for pediatric AML. The study is a collaboration between the Pediatric Blood and Marrow Transplant Consortium (PBMTC) and the Resource for Clinical Investigations in Blood and Marrow Transplantation (RCI-BMT) of the Center for International Blood and Marrow Transplant Research (CIBMTR). The study will enroll pediatric AML patients who undergo myeloablative HCT at PBMTC sites. The eligibility criteria for this non-therapeutic study mirror widely accepted criteria for allogeneic HCT in pediatric AML.. The study tests the hypothesis that assessment of pre-transplant and post-transplant MRD predicts 2-year outcomes following transplant. Two MRD methodologies are being studied: flow cytometry and WT1 PCR. The secondary hypothesis is that combining these 2 methodologies will improve the accuracy in predicting 2-year outcomes following ...
Definition of acute myeloid leukemia in the Financial Dictionary - by Free online English dictionary and encyclopedia. What is acute myeloid leukemia? Meaning of acute myeloid leukemia as a finance term. What does acute myeloid leukemia mean in finance?
Acute myeloid (myelogenous, myelocytic, myeloblastic) leukemia (AML) consists of a group of malignant disorders characterized by the replacement of normal bone marrow with abnormal, primitive hematopoietic cells. Although the cure rate has improved, treatments are associated with notable morbidity and mortality.
Symptoms of acute myeloid leukemia can be divided into those caused by a deficiency of normally functioning cells, those due to the proliferation and infiltration of the abnormal leukemic cell populat... more
Acute myeloid leukemia (AML) accounts for approximately 15-20% of all childhood leukemias, and despite dramatic improvements in treatment outcome, only approximately 70% of children with AML are cured.1 AML results from collaborating genetic aberrations in at least 2 different classes; type-I aberrations, inducing uncontrolled cell proliferation and/or survival, and type-II aberrations inhibiting cell differentiation. However, certain aberrations found in AML do not completely fit into our current definition of type-I and type-II aberrations.2 These aberrations concern epigenetic modifier genes involved in DNA methylation and histone modification, such as Ten-Eleven Translocation 2 (TET2), Isocitrate Dehydrogenase 1 (IDH1), IDH2, Enhancer of Zeste Homolog 2 (EZH2), DNA (cytosine-5)-Methyltransferase 3 Alpha (DNMT3A) and Additional Sex Combs Like-1 (ASXL1). Most of these genes are frequently mutated in adult AML patients with a prevalence varying between 12% to 35% per gene.3-7 Reports on ...
This study investigated the safety and secondary acute myeloid leukemia risk in children receiving dexrazoxane after anthracycline exposure.
TY - JOUR. T1 - Sonic hedgehog antagonists induce cell death in acute myeloid leukemia cells with the presence of lipopolysaccharides, tumor necrosis factor-α, or interferons. AU - Lu, Frank Leigh. AU - Yu, Ching Chia. AU - Chiu, Huei Hsuan. AU - Liu, Hsingjin Eugene. AU - Chen, Shao Yin. AU - Lin, Shufan. AU - Goh, Ting Yi. AU - Hsu, Hsin Chih. AU - Chien, Chih Han. AU - Wu, Han Chung. AU - Chen, Ming Shan. AU - Schuyler, Scott C.. AU - Hsieh, Wu Shiun. AU - Wu, Mei Hwan. AU - Lu, Jean. PY - 2013/8. Y1 - 2013/8. N2 - Summary: Due to the development of drug resistance, the outcome for the majority of patients with acute myeloid leukemia (acute myelogenous leukemia; AML) remains poor. To prevent drug resistance and increase the therapeutic efficacy of treating AML, the development of new combinatory drug therapies is necessary. Sonic hedgehog (Shh) is expressed in AML biopsies and is essential for the drug resistance of cancer stem cells of AML. AML patients are frequently infected by bacteria ...
CPX-351 Extends Overall Survival Over 7+3 in Older Patients With Secondary Acute Myeloid Leukemia - On Location, Other Meetings - ASH Clinical News
Multidrug resistance remains a major obstacle to effective treatment of patients with Acute Myelogenous Leukemia (AML). A growing body of evidence indicates that over-expression of the MDR1 gene,...
TY - JOUR. T1 - High Levels of Constitutive WAF1/Cip1 Protein are Associated with Chemoresistance in Acute Myelogenous Leukemia. AU - Zhang, Wei. AU - Kobayashi, Tohru. AU - Kornblau, Steven M.. AU - Gambel, Anne. AU - Claxton, David. AU - Deisseroth, Albert B.. PY - 1995/9/1. Y1 - 1995/9/1. N2 - The WAFl/Cipl gene product is an important regulator at the G, checkpoint in the cell cycle. WAFl/Cipl expression can be activated through p53-dependent and p53-independent pathways. The WAFl/Cipl protein binds to cyclin- dependent kinase complexes and inhibits the kinase activity that is required for cell cycle progression. In this preliminary study, we analyzed with Western blot assays the steady-state levels of the WAFl/Cipl protein in the leukemia cells of 100 untreated acute myelogenous leukemia (AML) patients. Normal bone marrow cells from six donors were used as a control. The results of these analyses showed that the levels of the WAFl/Cipl protein were very low in normal marrow cells and in the ...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
Sigma-Aldrich offers abstracts and full-text articles by [Meisheng Yu, Jishi Wang, Dan Ma, Shuya Chen, Xiaojing Lin, Qin Fang, Nana Zhe].
Leukemia are a heterogeneous group of cancers affecting the bone marrow and White Blood Cells (WBC). Leukemia is characterized by the rapid increase of abnormal blood cells growth or blasts, resulting in a decrease in the numbers of healthy, normal fully modified blood cells, leading to the typical symptoms of bleeding, anemia, and high risk of infection. Leukemia can grow along either the myeloid or lymphoid stem cell lines, it depends on the effect of genetic and epigenetic mutations on the progression of pluripotent stem cells to the various lines of mature cells which then pass into the blood. The effected line, combined with the rate of action and growth of disease reflects the four types of leukemias- Acute Myeloid Leukemia (AML), chronic lymphoblastic leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia. AML: Acute Myeloid Leukemia, is a serious condition, its the most common leukemia suffered by adult people. According to a report from American Cancer Society, the average age ...
Free Online Library: Acute myeloid leukemia diagnosis in the 21st century. by Archives of Pathology & Laboratory Medicine; Health, general Acute myelocytic leukemia Cytochemistry Cytogenetics
BACKGROUND: Associations between body mass index (BMI), outcome, and leukemia-related factors in children with acute myeloid leukemia (AML) remain unclear. We investigated associations between pretherapeutic BMI, cytogenetic abnormalities, and outcome in a large multinational cohort of children with AML.. METHODS: We included patients, age 2-17 years, diagnosed with de novo AML from the five Nordic countries (2004-2016), Hong Kong (2007-2016), the Netherlands and Belgium (2010-2016), and Canada and USA (1995-2012). BMI standard deviations score for age and sex was calculated and categorized according to the World Health Organization. Cumulative incidence functions, Kaplan-Meier estimator, Cox regression, and logistic regression were used to investigate associations.. RESULTS: In total, 867 patients were included. The median age was 10 years (range 2-17 years). At diagnosis, 32 (4%) were underweight, 632 (73%) were healthy weight, 127 (15%) were overweight, and 76 (9%) were obese. There was no ...
On July 20, 2018, the U.S. Food and Drug Administration approved ivosidenib (Tibsovo) for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.. Approval was based on an open-label, single-arm, multicenter clinical trial (AG120-C-001, ClinicalTrials.gov identifier NCT02074839) that included 174 adult patients with relapsed or refractory AML with an IDH1 mutation confirmed using the IDH1 Assay, the FDA-approved test for selection of patients with AML for treatment with ivosidenib. Ivosidenib was given orally at a starting dose of 500 mg daily until disease progression, unacceptable toxicity, or hematopoietic stem cell transplantation. The median treatment duration was 4.1 months (range, 0.1-39.5 months). Of the 174 patients, 21 (12%) received a stem cell transplant following ivosidenib treatment.. Safety and Efficacy. Efficacy was established on the basis of the rate of complete remission plus complete ...
Another name for Acute Myelogenous Leukemia is Acute Myelogenous Leukemia. Medications commonly used to control pain and inflammation in adults with acute ...
TY - JOUR. T1 - Detection of FUS-ERG chimeric transcript in two cases of acute myeloid leukemia with t(16;21)(p11.2;q22) with unusual characteristics. AU - Kim, Juwon. AU - Park, Tae Sung. AU - Song, Jaewoo. AU - Lee, Kyung A.. AU - Hong, Duk Jin. AU - Min, Yoo Hong. AU - Cheong, June Won. AU - Choi, Jong Rak. PY - 2009/10/15. Y1 - 2009/10/15. N2 - Reciprocal t(16;21)(p11;q22) is a rare chromosomal abnormality in acute myeloid leukemia (AML). The chimeric transcript FUS-ERG formed by this translocation which causes the replacement of RNA-binding domain of FUS (alias TLS) with the DNA-binding domain of ERG, and this event is thought to be responsible for leukemogenesis. Here we report two cases of AML with t(16;21)(p11.2;q22) showing unusual characteristics, and address the clinical, hematological, and molecular aspects of leukemia with t(16;21), along with a review of the literature.. AB - Reciprocal t(16;21)(p11;q22) is a rare chromosomal abnormality in acute myeloid leukemia (AML). The ...
In this issue of Clinical Cancer Research, Parkin and colleagues report on the identification of a subset of adult acute myelogenous leukemia (AML), in which the tumor suppressor NF1 is functionally inactive, resulting in increased Ras signaling and sensitivity to mammalian target of rapamycin (mTOR) inhibition (1). The authors found that AML CD34+/C38− cells with absent NF1 expression are sensitive to treatment with rapamycin, thus implicating mTOR as a therapeutic target within the leukemia-initiating compartment of a small subgroup of adult AML patients.. AML is a highly malignant hematopoietic neoplasm, characterized by a poor prognosis, especially in older patients. In addition to age, the major prognostic marker is cytogenetics, and the mutational status of selected genes (e.g., NPM1, FLT3) strongly influence prognosis in the 50% of AML cases that are cytogenetically normal (2). The treatment of AML has changed little in the past several decades, and the discovery of additional ...
Its important to know your acute myeloid leukemia (AML) subtype because it plays a large part in determining the type of treatment youll receive.
S100A8 and S100A9 are calcium-binding proteins predominantly expressed by neutrophils and monocytes and play key roles in both normal and pathological inflammation. Recently, both proteins were found to promote tumor progression through the establishment of premetastatic niches and inhibit antitumor immune responses. Although S100A8 and S100A9 have been studied in solid cancers, their functions in hematological malignancies remain poorly understood. However, S100A8 and S100A9 are highly expressed in acute myeloid leukemia (AML), and S100A8 expression has been linked to poor prognosis in AML. We identified a small subpopulation of cells expressing S100A8 and S100A9 in AML mouse models and primary human AML samples. In vitro and in vivo analyses revealed that S100A9 induces AML cell differentiation, whereas S100A8 prevents differentiation induced by S100A9 activity and maintains AML immature phenotype. Treatment with recombinant S100A9 proteins increased AML cell maturation, induced growth arrest, and
Clonal heterogeneity detected by karyotyping is a biomarker associated with adverse prognosis in acute myeloid leukemia (AML). Constitutive activation of the phosphatidylinositol-3-kinase-Akt-mechanistic target of rapamycin (PI3K-Akt-mTOR) pathway is present in AML cells, and this pathway integrates signaling from several upstream receptors/mediators. We suggest that this pathway reflects biologically important clonal heterogeneity. We investigated constitutive PI3K-Akt-mTOR pathway activation in primary human AML cells derived from 114 patients, together with 18 pathway mediators. The cohort included patients with normal karyotype or single karyotype abnormalities and with an expected heterogeneity of molecular genetic abnormalities. Clonal heterogeneity reflected as pathway mediator heterogeneity was detected for 49 patients. Global gene expression profiles of AML cell populations with and without clonal heterogeneity differed with regard to expression of ectopic olfactory receptors (a subset ...
TY - JOUR. T1 - Abstract 1114: IGFBP7 reduces acute myeloid leukemia stem cell survival without affecting normal hematopoiesis. AU - Cil, Meyram. AU - Vermue, Eline. AU - Zweegman, Sonja. AU - Smit, Marjon. AU - Schuurhuis, Gerrit Jan. AU - Klootwijk, Louise L. de Vos. AU - Menezes, Renee X.. AU - Tsui, Mei-Ling. AU - Smit, Linda. AU - Rutten, Arjo. AU - Gils, Noortje van. AU - Brocco, Fabio. AU - Roemer, Margaretha G.. AU - Ossenkoppele, Gert J.. AU - Verhagen, Han J.. AU - Rhenen, Anna van. AU - Janssen, Jeroen J.. AU - Denkers, Fedor. AU - Heukelom, Stan. PY - 2018/8/17. Y1 - 2018/8/17. U2 - 10.1158/1538-7445.am2018-1114. DO - 10.1158/1538-7445.am2018-1114. M3 - Article. VL - 78. SP - 1114. EP - 1114. JO - Cancer Research. JF - Cancer Research. SN - 0008-5472. IS - 13 Supplement. ER - ...
TY - JOUR. T1 - Expression of MDR1 gene in acute leukemia cells. T2 - Association with CD7+ acute myeloblastic leukemia/acute lymphoblastic leukemia. AU - Miwa, H.. AU - Kita, K.. AU - Nishii, K.. AU - Morita, N.. AU - Takakura, N.. AU - Ohishi, K.. AU - Mahmud, N.. AU - Kageyama, S.. AU - Fukumoto, M.. AU - Shirakawa, S.. N1 - Copyright: Copyright 2020 Elsevier B.V., All rights reserved.. PY - 1993. Y1 - 1993. N2 - MDR1 gene expression was examined in acute leukemia cells from 75 Japanese patients at diagnosis (50 with acute myeloblastic leukemia [AML]: 10 M1, 18 M2, 5 M3, 8 M4, 9 M5; 25 with acute lymphoblastic leukemia [ALL]: 13 B- precursor, 12 T-lineage). The results of MDR1 mRNA expression by reverse transcriptase polymerase chain reaction were confirmed by immunostaining using the anti-P-glycoprotein monoclonal antibody UIC2 and by a functional study using the rhodamine efflux test. Morphologically, AML M1 cases had the highest incidence of MDR1 gene expression (6 of 10 patients). ...
TY - JOUR. T1 - Clinical relevance of internal tandem duplication of the FLT3 gene in childhood acute myeloid leukemia. AU - Liang, Der Cherng. AU - Shih, Lee Yung. AU - Hung, Iou Jih. AU - Yang, Chao Ping. AU - Chen, Shu Huey. AU - Jaing, Tang Her. AU - Liu, Hsi Che. AU - Chang, Wan Hui. PY - 2002/6/15. Y1 - 2002/6/15. N2 - BACKGROUND. Recently, an internal tandem duplication of the FLT3 gene (FLT3/ITD) was found in approximately 20% of adult acute myeloid leukemia (AML) cases and associated with a poor outcome. However, there are few studies on FLT3/ITD in childhood AML, and the clinical significance of FLT3/ITD is thus unclear. METHODS. FLTS/ITD was analyzed in 80 children with de novo AML. The genomic DNA polymerase chain reaction (PCR) assay was performed to identify FLT3/ITD. Genescan analysis to determine the allelic distribution was then performed for those PCR products with aberrant bands. Direct sequencing of PCR products was also carried out in each sample with FLT3/ITD. RESULTS. The ...
Description of disease Acute nonlymphocytic leukemia. Treatment Acute nonlymphocytic leukemia. Symptoms and causes Acute nonlymphocytic leukemia Prophylaxis Acute nonlymphocytic leukemia
Synonyms for Adult Acute Leukemia in Free Thesaurus. Antonyms for Adult Acute Leukemia. 1 synonym for acute myeloid leukemia: acute myelocytic leukemia. What are synonyms for Adult Acute Leukemia?
TY - JOUR. T1 - Advances in immunotherapy for pediatric acute myeloid leukemia. AU - Bonifant, Challice L.. AU - Velasquez, Mireya Paulina. AU - Gottschalk, Stephen. N1 - Funding Information: The authors AML research is supported by grants from the Leukemia and Lymphoma Society, the Cancer Prevention Research Institute of Texas (RP160693), Alex Lemonade Stand Foundation, the Hyundai Hope on Wheels Foundation, the Damon Runyon Cancer Research Foundation, and the Ravitz Family Foundation. Publisher Copyright: © 2017 Informa UK Limited, trading as Taylor & Francis Group. Copyright: Copyright 2018 Elsevier B.V., All rights reserved.. PY - 2018/1/2. Y1 - 2018/1/2. N2 - Introduction: Achieving better disease control in patients diagnosed with acute myeloid leukemia (AML) has proven challenging. Overall survival has been impacted by addressing treatment related mortality with focused supportive care measures. Despite this improvement, it remains difficult to induce durable leukemia remissions despite ...
Our program is focused on producing new therapeutic candidates to prolong remission and potentially cure highly lethal cancers where patients have few alternative treatment options. We have selected Acute Myelogenous Leukemia (AML) as the initial clinical indication for evaluating our novel therapeutics, but anticipate a full development program encompassing many other types of solid tumor cancers. Our strategy is to develop an antibody that binds to and eliminates the cancer-forming stem cells in leukemia and other solid tumors. While current cancer treatments (e.g. surgery, chemotherapy, radiation) will frequently get rid of the bulk of the tumor, they rarely touch the tiny number of cancer stem cells that actually re-generate the masses of cancer cells that have been eliminated. When the latter occurs, the patient is described as having a relapse, leading to a disease recurrence with poor prognosis. Our strategy is to eliminate the small number of cancer-regenerating stem cells by targeting ...
TY - JOUR. T1 - Prognostic value of AML 1/ETO fusion transcripts in patients with acute myelogenous leukemia.. AU - Cho, Eun Kyung. AU - Bang, Soo Mee. AU - Ahn, Jeong Yeal. AU - Yoo, Seung Min. AU - Park, Pil Whan. AU - Seo, Yieh Hea. AU - Shin, Dong Bok. AU - Lee, Jae Hoon. PY - 2003/1/1. Y1 - 2003/1/1. N2 - BACKGROUND: The t (8;21) (q22;q22), which produces the fusion gene AML1/ETO, is associated with relatively good prognosis and, in particular, with a good response to cytosine arabinoside. Analysis of t (8;21) positive leukemic blasts has shown characteristic morphological and immunological features. We performed this study to investigate the incidence of AML1/ETO rearrangement in adult acute myelogenous leukemia (AML), especially in M2 subtype, to make a comparison of clinical, morphological and immunophenotypic characteristics between AML1/ETO rearrangement positive and negative group in patients with AML and to analyze the correlation with other biological parameters. METHODS: From May ...
TY - JOUR. T1 - Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses. AU - Choudhury, A.. AU - Liang, J. C.. AU - Thomas, E. K.. AU - Flores-Romo, L.. AU - Xie, O. S.. AU - Agusala, K.. AU - Sutaria, S.. AU - Sinha, I.. AU - Champlin, R. E.. AU - Claxton, D. F.. N1 - Copyright: Copyright 2020 Elsevier B.V., All rights reserved.. PY - 1999/2/1. Y1 - 1999/2/1. N2 - We have previously reported that leukemic dendritic cells (DC) can be generated ex vivo from myelomonocytic precursors in chronic myelogenous leukemia. In this study we report the generation of DC from acute mye1ogenous leukemia (AML) cells and their potent ability to stimulate leukemia-specific cytolytic activity in autologous lymphocytes. DC were generated in vitro using granulocyte-macrophage colony-stimulating factor+interleukin-4 in combination with either tumor necrosis factor-α or CD40 ligand (CD40L). Cells from 19 AML patients with a variety of chromosomal ...
MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Bone Marrow Transplantation. Child. Combined Modality Therapy. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Dexamethasone / administration & dosage. Etoposide / administration & dosage. Female. Graft vs Host Disease / etiology. Humans. Idarubicin / administration & dosage. Immunologic Factors / therapeutic use. Interleukin-2 / therapeutic use. Leukemic Infiltration. Radiotherapy, High-Energy. Recurrence. Salvage Therapy. Thioguanine / administration & dosage. Transplantation ...
The purpose of this report is to describe the results of stem cell transplantation as initial treatment for secondary acute myeloid leukemia (AML). Forty-six patients (median age 42 years) with secondary AML (17 therapy-related, 29 myelodysplasia-related) who had not received remission induction chemotherapy underwent allogeneic (n = 43) or syngeneic (n = 3) transplantation. The 5-year actuarial disease-free survival was 24.4%, and the cumulative incidences of relapse and nonrelapse mortality were 31.3% and 44.3%, respectively. Lower peripheral blood blast count was associated with a lower risk of relapse (P = .05) and shorter time from AML diagnosis to transplant was associated with a lower risk of nonrelapse mortality (P = .02) and improved disease-free survival (P = .026). Patients with therapy-related secondary AML tended to have lower disease-free survival (P = .16) and a higher relapse rate (P = .16) than patients whose leukemia was not therapy-related. The results of these 46 previously ...
Acute myelomonocytic leukemia (AMMoL) is a form of acute myeloid leukemia which involves a proliferation of CFU-GM myeloblasts and monoblasts. It is classified under M4 in the French-American-British classification (FAB).[1] It is classified under AML, not otherwise classified in the WHO classification.[2] Translocations have been observed.[3] Progression from myelodysplastic syndrome has been reported.[4] ...
TY - JOUR. T1 - t(1;7) in acute myeloblastic leukemia following myelodysplastic syndrome (RAEB-T). AU - Defferrari, R.. AU - Sessarego, M.. AU - Santini, G.. AU - Ajmar, F.. PY - 1988. Y1 - 1988. N2 - A case is described of myelodysplastic syndrome (MDS) refractory anemia type with an excess of blasts in transformation with early leukemic evolution (AML-M1). All bone marrow cells examined showed an unbalanced translocation t(1;7). The karyotype was 45, xy, -21, -7, + der dic t(1;7)(q12;q21). There are reports in the literature of the translocation t(1;7)(p11;p11), which leads to trisomy of the long arms of chromosome number 1 and monosomy of the long arms of chromosome number 7. In the case here described the breakpoints of the chromosomes involved in the translocation differ from the classic ones: in this case there is trisomy of the region 1q12→1qter and monosomy of the region 7q21→7qter. Some clinical and cytogenetic considerations are suggested.. AB - A case is described of ...
Acute leukemias represent the main malignancies occurring among children under the age of 15 years. Around 17% corresponds to acute myeloid leukemia (AML). The cytogenetic analysis of bone marrow complements the diagnosis of hematological malignancies, therefore finding chromosomal aberrations provides a more reliable prognosis of the disease. Among the cytogenetic aberrations, sole trisomy is frequent in malignant neoplasias, but few cases related to AML have been reported. We report a sole trisomy 6 in a pediatric patient diagnosed as AML M4 and poor progression. We carried out a literature review of AML patients with sole trisomy 6 and compared their evolution against AML patients with normal karyotype. This is the first case of pediatric AML M4 with this cytogenetic finding. Sole trisomy 6 is infrequently reported in AML but scarce in pediatric cases. Based on overall survival analysis, we suggest that sole trisomy 6 could be associated with poor prognosis, in both, adult as well as pediatric AML.
BackgroundAcute myeloid leukemia (AML) is the most common form of acute leukemia affecting adults, with incidence increasing with patient age. Previous studies have found that older AML patients, constituting the majority of the AML population, generally have poor outcomes, high healthcare expenditures, and median survival of
Myeloid sarcoma occurs in 1% - 9% of patients with myelogenous leukemia. Spinal epidural myeloid sarcoma is particularly rare, and its treatment has not been established. A 27-year-old woman complained of pain on her left chest, back around the scapula, and neck. Magnetic resonance imaging (MRI) showed a thoracic epidural tumor. One week after her visit, she developed motor weakness of her lower extremities and dysuria, and she was diagnosed with acute myelogenous leukemia (AML) on peripheral blood analysis. The epidural tumor was strongly suspected to be myeloid sarcoma. The paralysis of the lower extremities and bladder dysfunction were not progressive, and chemotherapy and local radiation therapy to the spine were performed. Improvement of paralysis and complete reduction of tumor volume were achieved by the combination of local low-dose radiation therapy and chemotherapy.
Downregulation of PDIA3 inhibits proliferation and invasion of human acute myeloid leukemia cells Qidong Ye,1 Pan Fu,2 Jiaying Dou,2 Nina Wang2 1Department of Pediatrics, Ningbo First Hospital, Ningbo Hospital of Zhejiang University, Ningbo, People’s Republic of China; 2Department of Hematology, Shanghai Children’s Hospital, Shanghai Jiao Tong University, Shanghai, People’s Republic of China Introduction: Acute myeloid leukemia (AML) is a common malignancy of the hematopoietic system. In bone marrow samples of AML patients, PDIA3 expression was higher than that in the samples of healthy controls. We aimed at exploring the effect of PDIA3 siRNA on proliferation, apoptosis, migration, and invasion of AML HL-60 and HEL cells.Materials and methods: RT-PCR was performed to identify PDIA3 expression. Cell proliferation was assessed by MTT. Flow cytometry analysis and transwell were used to detect cell apoptosis, migration and invasion. Gene set enrich-ment analysis (GSEA) was employed to
TY - JOUR. T1 - Blood and bone marrow transplantation for acute myeloid leukemia. AU - Villela, Luis M.. AU - Bolanos Meade, F Javier. PY - 2009. Y1 - 2009. N2 - Bone marrow transplantation is the treatment of choice for some patients with acute myeloid leukemia and myelodysplastic syndrome (MDS). Patients with high-risk disease, such as those with MDS, in second (or subsequent) complete remission or those with poor-risk cytogenetics will benefit the most from this approach. With current transplantation techniques, outcomes have improved over recent years. Although relapse and graft-versus-host disease still are important problems faced by these patients, novel approaches have been developed to decrease the risk of complications, with excellent results.. AB - Bone marrow transplantation is the treatment of choice for some patients with acute myeloid leukemia and myelodysplastic syndrome (MDS). Patients with high-risk disease, such as those with MDS, in second (or subsequent) complete remission ...
Mouse monoclonal antibody raised against native NCAM1. Native purified NCAM1 from KG-1 human acute myelogenous leukemia cell line. (MAB5003) - Products - Abnova
Myeloid sarcoma of the breast is a rare manifestation of acute myeloid leukaemia (AML). This report describes a patient who was diagnosed with AML FAB M2. Molecular analysis showed evidence of an NPM1 mutation (subtype A) and internal tandem duplications of the FLT3 gene (FLT3-ITD). Eight months after allogeneic stem cell transplantation, the patient developed a palpable mass in the left breast initially suspected as breast carcinoma. Core needle biopsy of the lesion resulted in diagnosis of myeloid sarcoma. Molecular analysis of formalin-fixed specimens of the breast tumour confirmed the known FLT3 and NPM1 gene mutations. Immunohistochemically, an aberrant cytoplasmic staining pattern for NPM1 and overexpression of FLT3 were demonstrated. The myeloid sarcoma showed complete transient resolution following treatment with the kinase inhibitor sorafenib. However, the patient developed bone marrow relapse and died in fatal cerebral haemorrhage 1 year after initial diagnosis of AML. In summary, ...
Results of the present study show for the first time that Chk1 undergoes activating phosphorylation in marrow blasts in vivo during cytarabine-containing induction therapy. Building on this result, we also show in human AML cell lines that the selective Chk1 inhibitor SCH 900776 abrogates cytarabine-induced S-phase arrest, increases cytarabine-induced apoptosis, and enhances the effects of cytarabine on colony formation. Likewise, SCH 900776 increases the effects of cytarabine in a majority of primary AML isolates but not normal myeloid progenitors in vitro. This sensitization was observed at SCH 900776 concentrations far below the approximate 5 μmol/L SCH 900776 peak levels observed at the maximum tolerated dose in solid tumor patients. These observations have potentially important implications for current efforts to enhance the efficacy of cytarabine-containing AML regimens.. Previous results have shown that cytarabine activates the ATR/Chk1 checkpoint in tissue culture cell lines in vitro ...
Minimal residual disease evaluation refers to a series of molecular and immunophenotypical techniques aimed at detecting submicroscopic disease after therapy. As such, its application in acute myeloid leukemia has greatly increased our ability to quantify treatment response, and to determine the chemosensitivity of the disease, as the final product of the drug schedule, dose intensity, biodistribution, and the pharmakogenetic profile of the patient. There is now consistent evidence for the prognostic power of minimal residual disease evaluation in acute myeloid leukemia, which is complementary to the baseline prognostic assessment of the disease. The focus for its use is therefore shifting to individualize treatment based on a deeper evaluation of chemosensitivity and residual tumor burden. In this review, we will summarize the results of the major clinical studies evaluating minimal residual disease in acute myeloid leukemia in adults in recent years and address the technical and practical issues still
Patients with hematologic malignancies are at higher risk for invasive fungal infections (IFI) mainly patients with acute myeloid leukemia. Antifungal prophylaxis can help to decrease the incidence of these infections and their related complications. Prospective study compared to historical control data included 136 newly diagnosed Acute Myeloid Leukemia patients treated at the National Cancer Institute, Cairo University from 2011 to 2014. The prospective group received primary Voriconazole compared to retrospective control regarding the infectious complications and incidence of fungal infection. Results showed that one hundred thirty-six (136) newly diagnosed pediatric AML patients were included in the study, 61 patients didnt receive antifungal prophylaxis (Non- prophylactic arm) while 75 patients received voriconazole prophylaxis (prophylactic arm). The median age among both groups was 5.5 years old. Thirty-one (50%) of the 61 patients in (non - prophylactic arm) and five (6.6%) of the 75 patients
This phase 3 study on Remission Rates in Childhood Acute Myeloid Leukemia (AML) Utilizing a Dose-Intensive Induction Regimen With or Without Gemtuzumab Ozogamicin was recently completed by Alan S. Gamis, MD, MPH, of the Childrens Mercy Hospitals and Clinics in Kansas City, Mo., and colleagues. The findings from this study were presented at the 52nd American Society of Hematology Annual Meeting and Exposition.
To identify novel anti-cancer agents, we created and screened a unique nutraceutical library for activity against acute myeloid leukemia (AML) cells. From this screen, we determined that glucopsychosine was selectively toxic toward AML cell lines and primary AML patient samples with no effect toward normal hematopoietic cells. It delayed tumor growth and reduced tumor weights in mouse xenograft models without imparting toxicity. Glucopsychosine increased cytosolic calcium and induced apoptosis through calpain enzymes. Extracellular calcium was functionally important for glucopsychosine-induced AML cell death and surface calcium channel expression is altered in AML cells highlighting a unique mechanism of glucopsychosines selectivity ...
TY - JOUR. T1 - Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia. T2 - A report from the Eastern Cooperative Oncology Group. AU - Litzow, Mark R.. AU - Othus, Megan. AU - Cripe, Larry D.. AU - Gore, Steven D.. AU - Lazarus, Hillard M.. AU - Lee, Sandra J.. AU - Bennett, John M.. AU - Paietta, Elisabeth M.. AU - Dewald, Gordon W.. AU - Rowe, Jacob M.. AU - Tallman, Martin S.. PY - 2010/1/1. Y1 - 2010/1/1. N2 - The treatment of relapsed acute myeloid leukaemia (AML) remains unsatisfactory. We conducted a phase II randomized trial where patients received intermediate-dose cytarabine for 4 d followed by gemtuzumab ozogamicin on day 5 (Arm A), or combined with liposomal daunorubicin for 3 d (Arm B), or cytarabine given for 5 d combined with cyclophosphamide for 3 d and topotecan by continuous infusion for 5 d (Arm C). Eligible patients had primary refractory AML, a first relapse after a remission of ,1 year, or a second or greater ...
Chemotherapy for induction of remission of childhood acute myeloid leukemia followed by marrow transplantation or multiagent chemotherapy: A report from the Childrens Cancer Group Academic Article ...
The isocitrate dehydrogenase (IDH1/IDH2) genes are metabolic enzymes, which are frequently mutated in acute myeloid leukemia (AML). The enzymes acquire neomorphic enzymatic activity when they mutated. We have investigated the frequency and outcome of the acquired IDH1/IDH2 mutations and the IDH1 SNP 105C | T (rs11554137) in 189 unselected de novo AML patients by polymerase chain reaction amplification followed by direct sequencing. The survival are presented in Kaplan Meier curves with log rank test. Multivariable survival analysis was conducted using Cox regression method, taking age, risk group, treatment, IDH1/2 mutations and IDH1 SNP105 genotype into account. Overall, IDH1/2 mutations were found in 41/187 (21.7%) of the AML patients. IDH1 codon 132 mutations were present in 7.9%, whereas IDH2 mutations were more frequent and mutations were identified in codon 140 and 172 in a frequency of 11.1% and 2.6%, respectively. The SNP 105C | T was present in 10.5% of the patients, similar to the normal
TY - JOUR. T1 - Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations. AU - Alvarado, Yesid. AU - Kantarjian, Hagop M.. AU - Luthra, Rajyalakshmi. AU - Ravandi, Farhad. AU - Borthakur, Gautam. AU - Garcia-Manero, Guillermo. AU - Konopleva, Marina. AU - Estrov, Zeev. AU - Andreeff, Michael. AU - Cortes, Jorge E.. PY - 2014/1/1. Y1 - 2014/1/1. N2 - BACKGROUND FLT3-internal tandem duplication (ITD) mutations are found in approximately 30% of patients with acute myeloid leukemia (AML). FLT3 inhibitors have shown clinical activity in AML with FLT3-ITD, but responses are usually short-lived. METHODS This study examined 69 FLT3-mutated patients with AML, who were treated with different FLT3 inhibitors to analyze emergence of new mutations. RESULTS At baseline, 87% of patients had an ITD mutation, 7% had a D835/I836 mutation, and 6% had combined ITD and D835/I836 mutations. Responses occurred ...
Accumulating evidence indicates that lncRNAs may have potential as new biomarkers to predict prognosis of different human cancers. HOTAIR lncRNA, transcribed from the human HOX locus, has been suggested to regulate gene expression of important target genes and up-regulation has been noted in malignancies. The role of HOX transcript antisense RNA in acute myeloid leukemia (AML) was investigated in the present case control study. HOTAIR expression was evaluated in blood samples of twenty five de novo AML patients and fifty healthy controls using real-time quantitative reverse transcription-PCR (qRT-PCR). Our results demonstrated no significant differences in HOTAIR lncRNA expression level between AML patients and healthy individuals. The obtained data indicate that HOTAIR is not an informative and reliable biomarker for AML diagnosis, although our results should be confirmed in further studies.
Between 1978 and 1988 (median follow up 5 1/2 years), 396 newly diagnosed adults with AML (age range 14-59 years, median 44) received STT comprising daily Adriamycin: 25mg/m2 for 3 days, Cytosine arabinoside (ara-C): 100mg/m2 bd and 6-thioguanine: 100mg/m2 bd, each for 7 days. A maximum of 6 cycles was administered with as short an intercycle time as possible. No further treatment was given. Complete remission (CR) was achieved in 243/396 patients (62%), 71 patients (18%) having resistant leukaemia and 82 (21%) dying within 6 weeks. Antecedent myelodysplasia and advanced age correlated unfavourably with achievement of CR (p = less than 0.001 and 0.005 respectively). Sixty nine patients continue in first remission between 2 1/2 and 12 years; the median duration of remission was 1 year. M3 morphology (p = 0.005) and absence of hepatosplenomegaly (p = 0.001) correlated favourably with duration of remission. Ninety one patients remain alive with an actuarial survival of 22% at 5 years. More recently,
"Acute Myeloid Leukemia Staging". Retrieved 26 August 2011. Mihova D. "Leukemia acute - Acute myeloid leukemia with minimal ... "Adult Acute Myeloid Leukemia Treatment". National Cancer Institute. 6 March 2017. Retrieved 19 December 2017. "Acute Myeloid ... Acute myeloid leukemia (AML) is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal ... Acute leukemias of ambiguous lineage (also known as mixed phenotype or biphenotypic acute leukemia) occur when the leukemic ...
Acute erythrocyte leukemia is a rare form of acute myeloid leukemia (less than 5% of AML cases) where the myeloproliferation is ... Acute erythroid leukemia is rare, accounting for only 3-5% of all acute myeloid leukemia cases. One study estimated an ... These cases are now likely to instead be classified as acute myeloid leukemia with myelodysplasia-related changes or therapy- ... Naiem F, Rao PN (2009). "Acute Myeloid Leukemia". Hematopathology: Morphology, Immunophenotype, Cytogenetics, and Molecular ...
Löwenberg B, Downing JR, Burnett A (Sep 30, 1999). "Acute myeloid leukemia". N Engl J Med (Review). 341 (14): 1051-62. doi: ... Gassmann W, Winfried; Löffler H. (1995). "Acute megakaryoblastic leukemia". Leuk. Lymphoma. 18 Suppl 1: Leukemia and Lymphoma. ... Leukemia is a malignancy producing of white blood cells in bone marrow. It can be a serious disease if not treated early. ... These cancers include leukemias, lymphomas, and myelomas. These particular types of cancers can arise as defected mature cell ...
Forms of acute leukemia include: Acute myeloid leukemia Acute erythroid leukemia Acute lymphoblastic leukemia T-cell acute ... Acute leukemia or acute leukaemia is a family of serious medical conditions relating to an original diagnosis of leukemia. In ... "How I treat mixed-phenotype acute leukemia". Blood. 125 (16): 2477-85. doi:10.1182/blood-2014-10-551465. "Acute Myeloid ... "Acute erythroid leukemia". Arch. Pathol. Lab. Med. 134 (9): 1261-70. doi:10.5858/2009-0350-RA.1. PMID 20807044. "Acute ...
"Chemotherapy for Acute Myeloid Leukemia (AML)". www.cancer.org. Retrieved 2019-11-06. "Acute Myeloid Leukemia (AML) Subtypes ... Juvenile myelomonocytic leukemia "Acute Myeloid Leukemia - Signs and Symptoms". "eMedicine - Acute Myelogenous Leukemia : ... Acute myelomonocytic leukemia (AMML) is a form of acute myeloid leukemia that involves a proliferation of CFU-GM myeloblasts ... "Acute myelomonocytic leukemia (FAB AML M4)". www.pathologyoutlines.com. Retrieved 2019-11-06. "Acute Myeloid Leukemia (AML)". ...
There are four main types of leukemia-acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic ... especially acute myeloid leukemia), and Fanconi anemia is a risk factor for developing acute myeloid leukemia. Mutation in ... "Typical treatment of acute myeloid leukemia (except promyelocytic M3)". Detailed Guide: Leukemia - Acute Myeloid (AML). ... Subtypes of AML include acute promyelocytic leukemia, acute myeloblastic leukemia, and acute megakaryoblastic leukemia. Chronic ...
There have been reports of hairy cell leukemia, acute myeloid leukemia, and acute myeloblastic leukemia associated with ... Maloisel F, Oberling F (January 1992). "Acute myeloid leukemia complicating sarcoidosis". Journal of the Royal Society of ... Reich JM (January 1985). "Acute myeloblastic leukemia and sarcoidosis. Implications for pathogenesis". Cancer. 55 (2): 366-9. ... In acute and subacute cases, physical examination usually reveals dry crackles. At least 5% of cases include pulmonary arterial ...
"Chemotherapy for Chronic Myeloid Leukemia". cancer.org. American Cancer Society. February 22, 2016. Retrieved June 22, 2017. " ... "Chemotherapy for Acute Lymphocytic Leukemia". cancer.org. American Cancer Society. February 18, 2016. Retrieved June 22, 2017 ... "Chemotherapy for Childhood Leukemia". cancer.org. American Cancer Society. February 3, 2016. Retrieved June 22, 2017. " ... and is used to treat some leukemias, lymphomas, and childhood cancers, as well as several other types of cancer and some non- ...
December 2010). "DNMT3A mutations in acute myeloid leukemia". The New England Journal of Medicine. 363 (25): 2424-33. doi: ... mutated genes identified in the Cancer Genome Atlas project DNMT3A mutations were most commonly seen in acute myeloid leukaemia ... Shih AH, Abdel-Wahab O, Patel JP, Levine RL (September 2012). "The role of mutations in epigenetic regulators in myeloid ...
22 January 2016). "New drugs in acute myeloid leukemia". Annals of Oncology. 27 (5): 770-8. doi:10.1093/annonc/mdw015. PMC ... "Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia". ... as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy". Blood. ... The most significant effort was invested in developing lestaurtinib for the treatment of acute myelogenous leukemia (AML). 24% ...
"Acute Myeloid Leukemia - Signs and Symptoms". Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD ... AMKL is commonly regarded as a subtype of acute myeloid leukemia (AML). More formally, it is classified under the AML-M7 ... Acute megakaryoblastic leukemia (AMKL) is life-threatening leukemia in which malignant megakaryoblasts proliferate abnormally ... Wang SA, Hasserjian RP (July 2015). "Acute Erythroleukemias, Acute Megakaryoblastic Leukemias, and Reactive Mimics: A Guide to ...
"Chemotherapy for Acute Myeloid Leukemia (AML)". Vokes, E. E. (2010). "Induction Chemotherapy for Head and Neck Cancer: Recent ...
... acute myeloid leukemia, chronic myelomonocytic leukemia, case reports of chronic lymphocytic leukemia and large granular ... familial myelodysplastic syndrome/acute myeloid leukemia (i.e. familial MDS/AML); 3) chronic myelomonocytic leukemia (i.e. CMML ... Churpek JE (December 2017). "Familial myelodysplastic syndrome/acute myeloid leukemia". Best Practice & Research. Clinical ... "Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome)" ( ...
Godwin CD, Gale RP, Walter RB (June 2017). "Gemtuzumab ozogamicin in acute myeloid leukemia". Leukemia. 31: 1855-1868. doi: ... "U.S. FDA Approves Inotuzumab Ozogamicin for Treatment of Patients with R/R B-cell precursor Acute Lymphoblastic Leukemia". ADC ... "BESPONSA® Approved in the EU for Adult Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia". 30 ... monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia ...
"What are the key statistics about acute myeloid leukemia?Key Statistics for Acute Myeloid Leukemia (AML)". American Cancer ... "Risk Factors for Acute Myeloid Leukemia (AML)". American Cancer Society. 2018-08-21. Archived from the original on 2019-04-23 ... About 30,000 cases of myeloid leukemia occur in the United States each year. Some evidence suggests that workplace exposure to ... "Risk Factors for Chronic Myeloid Leukemia". American Cancer Society. 2018-06-19. Archived from the original on 2018-12-12. ...
"Vitamin B6 Addiction in Acute Myeloid Leukemia". Cancer Cell. 37 (1): 71-84.e7. doi:10.1016/j.ccell.2019.12.002. ISSN 1535-6108 ...
Prognosis is very poor once chronic myelogenous leukemia reaches the accelerated phase; it behaves similarly to acute myeloid ... Accelerated phase chronic myelogenous leukemia is a phase of chronic myelogenous leukemia in which the disease is progressing. ... "Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: ... Chronic myeloid leukemia, All stub articles, Oncology stubs). ... Accelerated phase chronic myelogenous leukemia entry in the ...
... in acute myeloid leukemia. He is the Chief of the Laboratory of Myeloid Malignancies at the National Heart, Lung, and Blood ... Hourigan is best known for work on Measurable Residual Disease (MRD) and precision medicine in Acute Myeloid Leukemia (AML). ... "Mission Bio's Tapestri Platform Used to Distinguish Acute Myeloid Leukemia Clones from CHIP Clones". CISION PR Newswire. " ... Hourigan, C. "IMPACT OF CONDITIONING INTENSITY OF ALLOGENEIC TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA WITH GENOMIC EVIDENCE ...
Meani N, Alcalay M (September 2009). "Role of nucleophosmin in acute myeloid leukemia". Expert Review of Anticancer Therapy. 9 ... acute promyelocytic leukemia, myelodysplastic syndrome, and acute myelogenous leukemia. Heterozygous mice for NPM1 are ... Chen W, Rassidakis GZ, Medeiros LJ (November 2006). "Nucleophosmin gene mutations in acute myeloid leukemia". Archives of ... Of high importance is NPM involvement in acute myelogenous leukemia, where a mutated protein lacking a folded C-terminal domain ...
... including T-cell acute lymphoblastic Leukemia (T-ALL) and Acute Myeloid Leukemia (AML) and at least two BFLS patients have ... January 2011). "PHF6 mutations in adult acute myeloid leukemia". Leukemia. 25 (1): 130-4. doi:10.1038/leu.2010.247. PMC 3878659 ... April 2010). "PHF6 mutations in T-cell acute lymphoblastic leukemia". Nature Genetics. 42 (4): 338-42. doi:10.1038/ng.542. PMC ... October 2010). "T-cell acute lymphoblastic leukemia in association with Börjeson-Forssman-Lehmann syndrome due to a mutation in ...
... is indicated for the treatment of adults with relapsed or refractory acute myeloid leukemia with a susceptible ... Liu X, Gong Y (2019). "Isocitrate dehydrogenase inhibitors in acute myeloid leukemia". Biomarker Research. 7: 22. doi:10.1186/ ... sold under the brand name Rezlidhia is an anticancer medication used to treat relapsed or refractory acute myeloid leukemia. ... for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation". Rigel ...
One example would be acute myeloid leukemia (AML). The following are some of the gene count estimates of human chromosome 5. ...
... (MPAL) is a group of blood cancers (leukemia) which have combined features of myeloid and ... "mixed-phenotype acute leukemia" to include leukemias of ambiguous lineage, acute undifferentiated leukemias and natural killer ... acute undifferentiated leukemias and natural killer lymphoblastic leukemias. According to WHO criteria, myeloid lineage is ... The name "mixed-phenotype acute leukemia" was adopted by the World Health Organization in 2008 to include leukemias of ...
Jurcic, Joseph G.; Rosenblat, Todd L. (2014). "Targeted Alpha-Particle Immunotherapy for Acute Myeloid Leukemia". American ... Targets include leukemias, lymphomas, gliomas, melanoma, and peritoneal carcinomatosis. As in diagnostic nuclear medicine, ...
Ghanem H, Kantarjian H, Ohanian M, Jabbour E (Apr 2013). "The role of clofarabine in acute myeloid leukemia". Leukemia & ...
Emman Nimedez, 21, Filipino YouTuber, acute myeloid leukemia. James Partridge, 67, British charity executive (Changing Faces). ... John Felagha, 26, Nigerian footballer (Eupen). Larry Hedrick, 79, American businessman, leukemia. Barbara Judge, 73, American- ...
John Mecray, 80, American painter, acute myeloid leukemia. Richard P. Mills, 72, American educator, Commissioner of Education ... complications from leukemia. Bob Seidemann, 75, American rock album cover designer (Blind Faith) and photographer (Grateful ...
... acute myeloid leukemia, and lung cancer. Micro RNAs are important regulators of almost all cellular processes such as survival ... "MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia". Blood. 111 (10): 5078-5085. ... "MicroRNA Expression in Cytogenetically Normal Acute Myeloid Leukemia". New England Journal of Medicine. 358 (18): 1919-1928. ... "Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin". Proceedings of the ...
... (AEL) is a rare subtype of acute myeloid leukemia with 50 to 80 percent of eosinophilic cells in ... This entity need treatment like acute myeloid leukemia. However more rarely Eosinophilic leukemia may have underlying lymphoid ... "Acute Myeloid Leukemia (AML) Subtypes and Prognostic Factors". www.cancer.org. Retrieved 2022-02-03. Fournier, Benjamin; ... Patients with acute eosinophilic leukemia have a propensity for developing bronchospasm as well as symptoms of the acute ...
In rare cases, some MPNs such as primary myelofibrosis may accelerate and turn into acute myeloid leukemia. MPNs are classified ... Chronic myeloid leukemia Chronic myeloid leukemia (CML) has a presence of the hallmark Philadelphia Chromosome (BCR-ABL1) ... "Preventing Myelofibrosis from Progressing to Acute Myeloid Leukemia". Cure Today. Retrieved 2020-07-09. "Are Myeloproliferative ... "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia". Blood. 127 (20): ...
One notable example is dasatinib which has been approved for the treatment of chronic myeloid leukemia (CML) and Philadelphia ... acute lymphocytic leukemia (ALL). Dasatinib is also in clinical trials for the use in non-Hodgkin's lymphoma, metastatic breast ... Amsberg GK, Koschmieder S (2013). "Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia ... Breccia M, Salaroli A, Molica M, Alimena G (2013). "Systematic review of dasatinib in chronic myeloid leukemia". OncoTargets ...
... progenitor/stem cells in TEL/AML1-positive acute lymphoblastic leukemia are genetically and functionally normal". Blood. 100 (2 ... However, counting CD34+ mononuclear cells may overestimate myeloid blasts in bone marrow smears due to hematogones (B ... Loken M. Shah V. Civin CI.. (1987). "Characterization of myeloid antigens on human bone marrow using multicolour ... Leukemia Research. 9 (1): 1-9. doi:10.1016/0145-2126(85)90016-5. PMID 3857402. Tindle RW. Katz F. Martin H. Watt D. Catovsky D ...
"The Tim-3-galectin-9 Secretory Pathway is Involved in the Immune Escape of Human Acute Myeloid Leukemia Cells". EBioMedicine. ... Abedin MJ, Kashio Y, Seki M, Nakamura K, Hirashima M (May 2003). "Potential roles of galectins in myeloid differentiation into ... "Upregulation of Galectin-9 and PD-L1 Immune Checkpoints Molecules in Patients with Chronic Lymphocytic Leukemia". Asian Pacific ...
June 2007). "CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia". Proceedings of the National Academy ... and CD123 on different hematopoietic cell populations from pediatric patients with acute myeloid leukemia". Archives of Medical ... June 2011). "[CD96 expression on bone marrow mononuclear cells in 91 patients with acute leukemia]". Zhongguo Shi Yan Xue Ye ...
Furthermore, mutations of IDH2 and IDH1 were found in up to 20% of cytogenetically normal acute myeloid leukemia (AML). These ... March 2010). "The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting ... February 2015). "WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation". Molecular ...
May 2020). "Early Response to the Plant Toxin Stenodactylin in Acute Myeloid Leukemia Cells Involves Inflammatory and Apoptotic ...
"The interleukin 3 gene is located on human chromosome 5 and is deleted in myeloid leukemias with a deletion of 5q". Proc. Natl ... "Enhanced immune costimulatory activity of primary acute myeloid leukaemia blasts after retrovirus-mediated gene transfer of ... It is thought that this genetic change is the key in development of this leukemia type. Human IL-3 was first cloned in 1986 and ... In addition, IL-3 stimulates proliferation of all cells in the myeloid lineage (granulocytes, monocytes, and dendritic cells), ...
Faust was diagnosed with Acute myeloid leukemia in 2009 and died on 23 May 2011. Faust was a father of three. Rugby League ... Deaths from acute myeloid leukemia, Deaths from cancer in Queensland, Rugby league players from Queensland). ...
Acute myeloid leukemia (AML) is a rapidly progressing disease that remains one of the most deadly blood cancers, killing more ... The Leukemia & Lymphoma Society, Our History The Leukemia & Lymphoma Society, History Beat AML "The Leukemia & Lymphoma Society ... "2017 Annual Report". Leukemia & Lymphoma Society. Retrieved 8 October 2018. About The Leukemia & Lymphoma Society "The Leukemia ... The name of the organization was later changed to the Leukemia Society, then to the Leukemia Society of America in the 1960s, ...
G6PD is hypomethylated at K403 in acute myeloid leukemia, SIRT2 activates G6PD to enhance NADPH production and promote leukemia ... Glucose-6-phosphate dehydrogenase deficiency is very common worldwide, and causes acute hemolytic anemia in the presence of ...
"FDA approves Mylotarg for treatment of acute myeloid leukemia". U.S. Food and Drug Administration (FDA) (Press release). 1 ... In the United States, gemtuzumab ozogamicin is indicated for newly diagnosed CD33-positive acute myeloid leukemia (AML) for ... 2001). "Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia". Clin Cancer Res. 7 (6): 1490-6. PMID ... that is used to treat acute myeloid leukemia. The most common grade 3 and higher adverse reactions that occurred during ...
... including Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Systemic Mastocytosis and Myelodysplastic Syndromes. These studies ... also termed cancer stem cell in the context of cancer and leukemic stem cell in leukemia contexts. Valent investigates the ...
April 2016). "Natural killer cell immunosenescence in acute myeloid leukaemia patients: new targets for immunotherapeutic ... "PD-1+ memory phenotype CD4+ T cells expressing C/EBPalpha underlie T cell immunodepression in senescence and leukemia". ... Although myeloid cell production does not seem to decline with age, macrophages become dysregulated as a consequence of ...
... for treatment of acute myeloid leukemia. In August 2019, the company announced it would acquire Cavion Inc. for up to ~$310 ... In December, the company began clinical trial of intravenous Erwinaze in patients with Acute Lymphoblastic Leukemia. In January ...
19 July - Brendan Kehoe, 40, software developer and author, after a battle with acute myeloid leukemia. 4 August - Éamonn ...
Lymphoid and myeloid DCs evolve from lymphoid and myeloid precursors, respectively, and thus are of hematopoietic origin. By ... The disease may also present as a pDC leukemia, i.e. increased levels of malignant pDC in blood (i.e. >2% of nucleated cells) ... 2004). "pH-Dependent Entry of Severe Acute Respiratory Syndrome Coronavirus Is Mediated by the Spike Glycoprotein and Enhanced ... Three types of DCs have been defined in human blood: the CD1c+ myeloid DCs, the CD141+ myeloid DCs and the CD303+ plasmacytoid ...
Correlation of prognosis with bone marrow cytogenetic finding in acute lymphoblastic leukemia Unclassified ALL is considered to ... "Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms." Nature 13 Aug 2009; 460, 904-909. Gondek LP, Tiu R, ... has been increasingly recognized as an important predictor of outcome in acute lymphoblastic leukemia (ALL). NB: Balanced ... "Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from ...
... myeloid leukemia Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute ... in acute myelogenous leukemia, excluding the acute promyelocytic leukemia form, which is better treated with ATRA and/or ... Chemotherapy regimens used in acute myeloid leukemia). ... nonlymphocytic leukemia: a cancer and leukemia group B study ( ... This is because vinca alkaloids are rapidly deactivated in myeloid cells by their enzyme myeloperoxidase. So the vinca ...
"A novel fusion between MOZ and the nuclear receptor coactivator TIF2 in acute myeloid leukemia". Blood. 91 (9): 3127-33. doi: ...
He died on November 23, 2012, from complications of acute myeloid leukemia. Hagman was born on September 21, 1931, in Fort ... Deaths from acute myeloid leukemia, Deaths from myelodysplastic syndrome, Film directors from California, Film directors from ... at Medical City Dallas Hospital in Dallas following complications from acute myeloid leukemia, after being interviewed for the ...
... and MOZ-CBP genes expressed in acute myeloid leukemia (AML), and the TMPRSS2-ETS chimera associated with overexpression of the ... For instance, gene fusion in chronic myelogenous leukemia (CML) leads to an mRNA transcript that encompasses the 5′ end of the ... breakpoint cluster region protein (BCR) gene and the 3′ end of the Abelson murine leukemia viral oncogene homolog 1 (ABL) gene ...
"High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients". Blood. 101 (3): ... "High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients". Blood. 101 (3): ... of BCR-ABL and AML1/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia". ... Since it was first identified in murine myeloid leukemia as a common site of retroviral integration into the chromosome, EVI1 ...
... and thrombophilia as well as somatically acquired disorders including Myeloproliferative neoplasms and Acute myeloid leukemia ...
... caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia ...
... hairy cell leukemia (10%), and myeloma (some). It tends to be negative in acute myeloid leukemia, chronic lymphocytic leukemia ... It is also a common acute lymphocytic leukemia antigen that is an important cell surface marker in the diagnosis of human acute ... Acute lymphoblastic leukemia (ALL) cells are CD10+. Follicular lymphoma (follicle centre cell lymphoma) are CD10+. Burkitt ... and common acute lymphoblastic leukemia antigen (CALLA) is an enzyme that in humans is encoded by the MME gene. Neprilysin is a ...
... signs and symptoms respectively of acute myeloid leukemia or lymphoma T-lymphoblastic leukemia/lymphoma or lymphocytic leukemia ... However, and unlike most cases of myeloid leukemia, FIP1L1-PDGFRA fusion gene-induced eosinophil leukemia diseases (including a ... examination may be useful in excluding other malignant diseases associated with eosinophilia such as acute myeloid leukemia but ... Translocations between this 17q21.2 locus and several other loci have been associated with acute promyelocytic leukemia. Three ...
Cases may be acute (sudden onset with < 3 month duration) and monophonic, acute and recurrent, or chronic. The signs and ... Innate immune stimulation by bacteria and cellular stress is normally suppressed by myeloid suppression while inducible Treg ... retinoblastoma lymphoma malignant melanoma leukemia reticulum cell sarcoma The disease course, anatomy, and laterality can vary ... Wakefield D, Chang JH, Amjadi S, Maconochie Z, Abu El-Asrar A, McCluskey P (April 2011). "What is new HLA-B27 acute anterior ...
... and mir126* are overexpressed in acute myeloid leukemia. mir-126 expression is reduced in colorectal cancer. mir-126 ... Li Z, Chen J (2011). "In vitro functional study of miR-126 in leukemia". MicroRNA and Cancer. Methods in Molecular Biology. Vol ...
Following John-Henry's unexpected illness and death from acute myeloid leukemia on March 6, 2004, John-Henry's body was also ... Williams continued his involvement in the Jimmy Fund, later losing a brother to leukemia, and spending much of his spare time, ... Williams's brother Danny and his son John-Henry both died of leukemia. In his last years, Williams suffered from cardiomyopathy ... ". "John Henry Williams dies of leukemia at 35". March 13, 2004. Archived from the original on November 27, 2016. Retrieved ...
Treatment options for adult acute myeloid leukemia (AML) include chemotherapy, radiation therapy, stem cell transplant, and ... Stages of Acute Myeloid Leukemia. Key Points. *Once acute myeloid leukemia (AML) has been diagnosed, tests are done to find out ... Acute Myeloid Leukemia Treatment (PDQ®)-Patient Version. On This Page. *General Information About Acute Myeloid Leukemia ... General Information About Acute Myeloid Leukemia. Go to Health Professional Version. Key Points. *Adult acute myeloid leukemia ...
... called acute myeloid leukemia. Explore symptoms, inheritance, genetics of this condition. ... Cytogenetically normal acute myeloid leukemia (CN-AML) is one form of a cancer of the blood-forming tissue (bone marrow) ... medlineplus.gov/genetics/condition/cytogenetically-normal-acute-myeloid-leukemia/ Cytogenetically normal acute myeloid leukemia ... In acute myeloid leukemia. , the bone marrow makes large numbers of abnormal, immature white blood cells called myeloid blasts ...
Acute myelogenous leukemia (AML) is a malignant disease of the bone marrow in which hematopoietic precursors are arrested in an ... encoded search term (Acute Myeloid Leukemia (AML)) and Acute Myeloid Leukemia (AML) What to Read Next on Medscape ... Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 1994 Oct ... TET2 Mutations Improve the New European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: A Cancer and Leukemia Group ...
Knowing the subtype of acute myeloid leukemia can be very important, as it can affect outlook and treatment options. Learn how ... Classification of acute myeloid leukemia. UpToDate. 2018. Accessed at www.uptodate.com/contents/classification-of-acute-myeloid ... Physician Data Query (PDQ). Adult Acute Myeloid Leukemia Treatment. 2018. Accessed at www.cancer.gov/types/leukemia/hp/adult- ... but are leukemias that have both lymphocytic and myeloid features. They are sometimes called mixed phenotype acute leukemias ( ...
See what to know about treating relapsed or refractory acute myeloid leukemia, including chemotherapy, stem cell ... Acute Myeloid Leukemia: Treatment for Relapsed or Refractory Disease By Maxine Lipner ... While many people do well with initial treatment for acute myeloid leukemia (AML), some require more treatment. These people ... With a stem cell transplant, after bone marrow that has any leukemia cells is first destroyed, it is then replaced with stem ...
What Is Acute Myeloid Leukemia?. Acute myeloid leukemia (AML) happens when the body makes too many immature blood cells. These ... Acute Myeloid Leukemia (AML). What Is Leukemia?. Leukemia is a cancer that mostly affects white blood cells. White blood cells ... How Is Acute Myeloid Leukemia Diagnosed?. Doctors use special tests to check for leukemia. These include:. *Blood tests. Tests ... What Causes Acute Myeloid Leukemia?. Doctors dont know exactly what causes leukemia. But some things can make kids more likely ...
While advances in acute myeloid leukemia (AML) research have led to the development of a variety of novel treatments for the ... Clinical Challenges: Treating TP53-Mutated Acute Myeloid Leukemia. - Its of paramount importance that we do better for these ...
Leukemia - Acute Myeloid - AML - Childhood: Additional Resources. Approved by the Cancer.Net Editorial Board, 08/2019 ... Leukemia - Acute Myeloid - AML - Childhood - Questions to Ask the Health Care Team up ... Leukemia - Acute Myeloid - AML - Childhood Guide. Cancer.Net Guide. Leukemia - Acute Myeloid - AML - Childhood ... Leukemia - Acute Myeloid - AML - Childhood , *Leukemia - Acute Myeloid - AML - Childhood: Additional Resources ...
Diseases : Acute Myeloid Leukemia : CK(242) : AC(115). Pharmacological Actions : Antiproliferative : CK(6801) : AC(5032), ... Additional Keywords : Acute Myeloid Leukemia, Antiproliferative : CK(65) : AC(52), Apoptotic, Cell cycle arrest, ... activates TET2 in leukemic cells and significantly improves overall survival in elderly patients with acute myeloid leukemia. ...
Scientists have discovered the first compound which kills resistant cancer cells in acute myeloid leukemia but spares healthy ... What is Acute Myeloid Leukemia?. Acute myeloid leukemia (AML) is a type of leukemia which develops in cells that go onto ... Leukemia Cancer and Homeopathy Parkinsons Disease Surgical Treatment Chronic Myeloid Leukemia Acute Myeloid Leukemia Colorectal ... What Is Acute Myeloid Leukemia? - (https://www.cancer.org/cancer/acute-myeloid-leukemia/about/what-is-aml.html) ...
Assistance with the prescription drugs and biologics used in the treatment of Acute Myeloid Leukemia. Click here to see if you ... About Acute Myeloid Leukemia. Acute myeloid leukemia (AML) starts in the bone marrow (the soft inner part of certain bones, ... "Acute" means that this leukemia can progress quickly if not treated, and would probably be fatal in a few months. "Myeloid" ... 1. You are being treated for Acute Myeloid Leukemia. Please make sure that HealthWell currently has a fund for your diagnosis/ ...
Acute myeloid leukemia - Homo sapiens (human) [ Pathway menu , Organism menu , Pathway entry , Download KGML , Show description ... Acute myeloid leukemia (AML) is a disease that is characterized by uncontrolled proliferation of clonal neoplastic cells and ... AML accounts for approximately 80% of all adult leukemias and remains the most common cause of leukemia death. Two major types ... Alterations in myeloid transcription factors governing hematopoietic differentiation provide second necessary event for ...
... is anticipated to gain lucrative growth over the forecast period owing to the rising incidences of acute myeloid leukemia (AML) ... Acute Myeloid Leukemia Therapeutics Market, Industry Report, 2025 GVR Report cover Acute Myeloid Leukemia Therapeutics Market ... The global acute myeloid leukemia therapeutics market is anticipated to gain lucrative growth over the forecast period as a ... Rising incidences of acute myeloid leukemia therapeutics are attributed to factors such as genetic mutations, unhealthy ...
Acute Myeloid Leukemia Leukemia Genetic and Rare Diseases Information Center resources: Myeloid Leukemia Acute Myeloid Leukemia ... Familial acute myeloid leukemia with mutated CEBPA Cytogenetically normal acute myeloid leukemia Core binding factor acute ... SEL24/MEN1703 in Patients With Acute Myeloid Leukemia. The safety and scientific validity of this study is the responsibility ... patients with diagnosis of Acute Myeloid Leukemia, all comers (completed) and bearing IDH1 or IDH2 mutation (open for ...
... hymeglusin may be attributed to the positive increase in the expression levels of HMGCS1 and multiple upregulated pro-leukemia ... Venetoclax is used for the priority treatment of elderly patients with acute myeloid leukemia (AML). Resistance or intolerance ... Venetoclax is used for the priority treatment of elderly patients with acute myeloid leukemia (AML). Resistance or intolerance ... Aryal S, Zhang Y, Wren S, Li C, Lu R. Molecular Regulators of HOXA9 in Acute Myeloid Leukemia. FEBS J (2021). doi: 10.1111/febs ...
We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.. ...
An ongoing international multi-center Phase II study is set to include patients with acute myeloid leukemia, acute ... Acute myeloid leukemia patients unable to find a matched donor for a life-saving stem cell transplant may soon have expanded ... Acute Myeloid Leukemia Drug Granted Second Orphan Drug Status .social-ris-container { display: flex; justify-content: space- ... In earlier studies in which high-risk leukemia patients with poor prognosis received escalating doses of ATIR after a ...
... for treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected ... FDA approves gilteritinib for relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutatation. * Share ... FDA approves gilteritinib for relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutatation ... for treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected ...
... acute myeloblastic leukemia, acute granulocytic leukemia or acute nonlymphocytic leukemia. Pediatric cancer specialists at ... is a childhood bone marrow cancer also called acute myelogenous leukemia, ... AML is also called acute myelogenous leukemia, acute myeloblastic leukemia, acute granulocytic leukemia or acute nonlymphocytic ... Acute myeloid leukemia (AML), is a childhood bone marrow cancer also called acute myelogenous leukemia, acute myeloblastic ...
Invasive Fungal Disease, Isavuconazole Treatment Failure, and Death in Acute Myeloid Leukemia Patients Anne-Pauline Bellanger. ... Invasive Fungal Disease, Isavuconazole Treatment Failure, and Death in Acute Myeloid Leukemia Patients. ...
Pharmacologic Inhibition of STAT5 in Acute Myeloid Leukemia. Leukemia 2018, 32, 1135-1146. [Google Scholar] [CrossRef][Green ... acute myeloid leukemia; tyrosine kinase inhibitor; FMS-like tyrosine kinase 3; targeted therapy; ponatinib; cabozantinib; WS6; ... Döhner, H.; Weisdorf, D.J.; Bloomfield, C.D. Acute Myeloid Leukemia. N. Engl. J. Med. 2015, 373, 1136-1152. [Google Scholar] [ ... Patients with Acute Myeloid Leukemia and an Activating Mutation in FLT3 Respond to a Small-Molecule FLT3 Tyrosine Kinase ...
The results suggest that quinacrine have repositioning potential for treatment of acute myeloid leukemia by targeting of ... acute myeloid and lymphocytic leukemias as well as peripheral blood mononuclear cells (PBMC) were tested in response to 1266 ... Mining the NCI-60 and the NextBio databases demonstrated leukemia sensitivity and the ability of quinacrine to reverse myeloid ... was performed using the NextBio bioinformatic software using gene expression analysis of drug exposed acute myeloid leukemia ...
Self help guide on how to live through Acute Myeloid Leukemia (AML). ... Thriving with Acute Myeloid Leukemia. Speaker Dr. Harry Erba, Survivor Debbie Beavers ... A study shows blood donors that do not have cancer including leukemia, 10% over 65 who donated find genetic changes commonly ...
There are many treatment choices for acute myeloid leukemia. The best one for you depends on a number of factors. ... Acute Myeloid Leukemia (AML): Treatment Choices There are many treatment choices for acute myeloid leukemia (AML). Which one ... These medicines are used to treat a subtype of AML called acute promyelocytic leukemia (APL). Theyre not used for other types ... Acute Lymphocytic Leukemia (ALL): Radiation Therapy * Acute Lymphocytic Leukemia (ALL): Stem Cell Transplant ...
... inhibitor panobinostat potentiates anthracycline and cytarabine cytotoxicity in acute myeloid leukemia (AML) cells. We ... Inhibition with Panobinostat Combined with Intensive Induction Chemotherapy in Older Patients with Acute Myeloid Leukemia: ... one therapy-related myeloid neoplasm, and one myelodysplastic syndrome with excess blasts-2. No dose-limiting toxicities ... Leukemia, Myeloid, Acute / diagnosis * Leukemia, Myeloid, Acute / drug therapy* * Leukemia, Myeloid, Acute / metabolism ...
... has shown promising results for treatment of relapsed or refractory acute myeloid leukemia (AML), according to findings from a ... has shown promising results for treatment of relapsed or refractory acute myeloid leukemia (AML), according to findings from a ... has shown promising results for treatment of relapsed or refractory acute myeloid leukemia (AML), according to findings from a ... Immunotherapy combination and chemotherapy show encouraging results in Phase II acute myeloid leukemia study. MD Anderson trial ...
Keywords: portal hypertension, acute myeloid leukemia, myeloproliferative disease, splenomegaly, esophageal varices JOURNAL ... Bone marrow examination revealed de novo acute myeloid leukemia. Although portal hypertension has been reportedly associated ... A case of portal hypertension complicated with de novo acute myeloid leukemia ... it has never been reportedly complicated with de novo acute myeloid leukemia. ...
... on independent educational programming designed to help address knowledge gaps in the diagnosis and treatment of acute myeloid ... ASH and Partners Receive Grant to Address Knowledge Gaps in Acute Myeloid Leukemia Care. Nov 08 ... ASH and Partners Receive Grant to Address Knowledge Gaps in Acute Myeloid Leukemia Care ... "Acute Myeloid Leukemia MATTERS: A Multidisciplinary Approach To Testing and Diagnosis, Evaluation of Risk, and Personalized ...
... ... lung metastases and relapsed or refractory acute myeloid leukemia (AML).. In addition to the moderated portion of the event, ... today announced it will host the Virtual Investor Innovations in Acute Myeloid Leukemia Spotlight Event featuring Moleculin ...
Background The molecular determinants of clinical responses to decitabine therapy in patients with acute myeloid leukemia (AML ... TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. TP53 and Decitabine in Acute Myeloid Leukemia and ... Background The molecular determinants of clinical responses to decitabine therapy in patients with acute myeloid leukemia (AML ...
  • An ongoing international multi-center Phase II study is set to include patients with acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome to corroborate and extend the safety and efficacy results from the earlier studies. (pharmacytimes.com)
  • I. Determine the maximum tolerated dose of fludarabine and cytarabine when combined with augmerosen (G3139) in patients with refractory or relapsed acute myeloid leukemia or acute lymphoblastic leukemia and recommend a starting dose for phase II studies. (knowcancer.com)
  • Inhibition of the RacGEF VAV3 by the small molecule IODVA1 impedes RAC signaling and overcomes resistance to tyrosine kinase inhibition in acute lymphoblastic leukemia. (cincinnatichildrens.org)
  • Acute lymphoblastic leukemia (ALL) / lymphoblastic lymphoma (LBL), also known as acute lymphocytic leukemia / lymphoma or acute lymphoid leukemia, is a cancer of precursor B-cell, T-cell, or other cell types in which immature lymphoid cells accumulate in blood, bone marrow, or other tissue. (logicalimages.com)
  • [ 1 ] and French-American-British (FAB)2 classifications for acute lymphoblastic leukemia (ALL) are provided below. (medscape.com)
  • The WHO classifies ALL as B-lymphoblastic leukemia/lymphoma or T-lymphoblastic leukemia/lymphoma. (medscape.com)
  • Acute myeloid leukemia (AML), is a childhood bone marrow cancer also called acute myelogenous leukemia, acute myeloblastic leukemia, acute granulocytic leukemia or acute nonlymphocytic leukemia. (lvhn.org)
  • AML is also called acute myelogenous leukemia, acute myeloblastic leukemia, acute granulocytic leukemia or acute nonlymphocytic leukemia. (lvhn.org)
  • Acute myeloblastic leukemia (AML) is a malignant bone marrow disease. (bvsalud.org)
  • Also referred to as acute myeloblastic leukemia, you will note an overabundance of abnormal immature white blood cells. (cdc.gov)
  • The flow cytometry panel should be sufficient to distinguish AML (including acute promyelocytic leukemia), T-ALL (including early T-cell precursor leukemias), B-cell precursor ALL (B-ALL), and AL of ambiguous lineage for all patients diagnosed with AL. (medscape.com)
  • For patients with suspected acute promyelocytic leukemia (APL), ensure rapid detection of PML-RARA. (medscape.com)
  • While advances in acute myeloid leukemia (AML) research have led to the development of a variety of novel treatments for the disease, finding optimal strategies to treat AML patients with TP53 mutations remains a critical unmet need. (medpagetoday.com)
  • Vitamin C with decitabine activates TET2 in leukemic cells and significantly improves overall survival in elderly patients with acute myeloid leukemia. (greenmedinfo.com)
  • The purpose of the clinical trial is to identify the maximum tolerated dose of SEL24/MEN1703 and to further investigate its safety profile in patients with Acute Myeloid Leukemia. (clinicaltrials.gov)
  • Phase I/II, open-label, multi-center, dose escalation study to estimate the maximum tolerated dose of SEL24/MEN1703 in patients with Acute Myeloid Leukemia. (clinicaltrials.gov)
  • The clinical trial will investigate the safety profile and anti-leukemic activity of SEL24/MEN1703 in patients with Acute Myeloid Leukemia and that have no standard therapeutic options available. (clinicaltrials.gov)
  • Venetoclax is used for the priority treatment of elderly patients with acute myeloid leukemia (AML). (frontiersin.org)
  • Acute myeloid leukemia (AML) is a common hematological malignancy in adults, primarily in older patients. (frontiersin.org)
  • Acute myeloid leukemia patients unable to find a matched donor for a life-saving stem cell transplant may soon have expanded options for a mismatched donor. (pharmacytimes.com)
  • In earlier studies in which high-risk leukemia patients with poor prognosis received escalating doses of ATIR after a haploidentical stem cell transplant, the drug exhibited long-term safety, efficacy, and proof of concept in terms of the absence of life-threatening acute graft-versus-host-disease. (pharmacytimes.com)
  • On November 28, 2018, the Food and Drug Administration approved gilteritinib (XOSPATA, Astellas Pharma US Inc.) for treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test. (fda.gov)
  • To find drugs suitable for repositioning for use against leukemia, samples from patients with chronic lymphocytic, acute myeloid and lymphocytic leukemias as well as peripheral blood mononuclear cells (PBMC) were tested in response to 1266 compounds from the LOPAC 1280 library (Sigma). (nature.com)
  • Fifteen patients had de novo AML, six AML with myelodysplasia-related changes, two AML with prior myeloproliferative neoplasm, one therapy-related myeloid neoplasm, and one myelodysplastic syndrome with excess blasts-2. (nih.gov)
  • This week, we're covering the U.S. Food and Drug Administration (FDA) approval of a doublet therapy in certain populations of patients with newly diagnosed acute myeloid leukemia. (ascopost.com)
  • Acute myeloid leukemia (AML) patients with NPM1 mutations demonstrate a superior response to standard chemotherapy treatment. (jci.org)
  • For patients with acute myeloid leukemia who are in a stage of complete remission and undergo stem cell transplantation, long-term survival outcomes are excellent. (fredhutch.org)
  • These individuals' baseline characteristics and outcomes were compared to those of 1,604 patients with DDX41 wild-type ( DDX41 WT ) AML, representing a prevalence of 5%, in 5 prospective Acute Leukemia French Association/French Innovative Leukemia Organization studies. (physiciansweekly.com)
  • Another example is Kaiser Permanente, which has decided that only one of three Kaiser institutions will treat patients with acute leukemia. (managedhealthcareexecutive.com)
  • BACKGROUND: In patients with acute myeloid leukemia (AML) a combination of methods must be used to classify the disease, make therapeutic decisions, and determine the prognosis. (eur.nl)
  • Physician researchers at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) are among an initial group of 14 U.S. academic cancer centers participating in a Leukemia and Lymphoma Association-sponsored trial to explore the feasibility and efficacy of guiding treatment decisions with prospective genetic profiling of acute myeloid leukemia (AML) in older patients. (umms.org)
  • Results from the first cohort of patients enrolled in the Study of Biomarker-Based Treatment of Acute Myeloid Leukemia trial ( NCT03013998 ), also known as the Beat AML ® Master Clinical Trial, were published in December 2020 in Nature Medicine. (umms.org)
  • In 2001, pharmaceutical companies began to introduce leukemia drugs to the market that significantly improved the quality of life for patients living with AML. (waterskraus.com)
  • San Diego, CA-Induction therapy with a liposomal formulation of cytarabine and daunorubicin CPX-351 (Vyxeos) is superior to cytarabine plus daunorubicin (7+3 regimen) in patients with acute myeloid leukemia (AML), according to a subgroup analysis of a large phase 3 clinical trial that was presented at the 2016 American Society of Hematology (ASH) meeting. (ahdbonline.com)
  • FUJIFILM Corporation (President: Kenji Sukeno) announced the commencement of a Phase I clinical trial of its anti-cancer drug FF-10101 in the Unites States in patients with relapsed or refractory acute myeloid leukemia (AML). (sonosite.com)
  • FF-10101 also demonstrated high efficacy in preclinical mouse models using primary cells from leukemia patients with the ITD or TKD mutation, and therefore promising efficacy in clinical trials is expected. (sonosite.com)
  • T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. (medscape.com)
  • In this video, Drs. Richard Stone, Courtney DiNardo, and Eunice Wang discuss the management of newly diagnosed older patients with acute myeloid leukemia (AML). (ascopost.com)
  • CD56 expression on the surface of leukemic cells in acute myeloid leukemia (AML) has been reported to correlate with higher rate of relapse and to be associated with poor outcome when patients are treated with conventional intensive chemotherapy. (ashpublications.org)
  • It is the first approved targeted cancer therapy for patients with relapsed or refractory acute myeloid leukemia (R/R AML), specifically, those screened by a complementary FDA-approved test and found to be carrying a mutated isocitrate dehydrogenase-1 (IDH1) gene. (pepid.com)
  • This is good news for about 6-10% of AML patients carrying this specific mutation who now have an acute myeloid leukemia treatment option. (pepid.com)
  • Patients can now avail of an acute myeloid leukemia treatment option that has been associated with complete remission and lessens the likelihood of needing blood transfusions. (pepid.com)
  • FDA Approves First Targeted Treatment for Patients with Relapsed or Refractory Acute Myeloid Leukemia Who Have a Certain Genetic Mutation. (pepid.com)
  • FDA Grants Approval of TIBSOVO®, the First Oral, Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH1 Mutation. (pepid.com)
  • This study aimed to characterize the psychological condition presented by the adult patients towards the Acute Myeloid Leukemia (AML). (bvsalud.org)
  • We present 2 cases of IFD and isavuconazole treatment failure in acute myeloid leukemia (AML) patients with prolonged neutropenia after hematopoietic stem-cell transplantation (SCT). (cdc.gov)
  • This project is being done to determine the highest safely tolerated dose of voruciclib in patients that have relapsed and/or refractory B cell type cancers or acute myeloid leukemia. (froedtert.com)
  • Ziftomenib, a potent and selective menin inhibitor, is currently in development for patients with NPM1-mutant and KMT2A-rearranged acute myeloid leukemia. (wjbf.com)
  • The Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndromes (MDS) Moon Shot has opened two clinical trials to address a crucial problem for MDS patients: swift progression when their disease resists a crucial class of drugs called hypomethylating agents. (mdanderson.org)
  • Yin X , Huang H , Huang S , Xu A , Fan F , Luo S , Yan H , Chen L , Sun C , Hu Y . A Novel Scoring System for Risk Assessment of Elderly Patients With Cytogenetically Normal Acute Myeloid Leukemia Based on Expression of Three AQP1 DNA Methylation-Associated Genes. (wjgnet.com)
  • Here we investigated the effect of AdC on HLA-G expression in malignant hematopoetic cells isolated from patients with acute myeloid leukemia (AML) and chronic lymphocytic leukemia (B-CLL). (elis.sk)
  • An expert describes the considerations in choosing to treat acute myeloid leukemia patients with venetoclax. (targetedonc.com)
  • Neutropenic fever (NF) is a common and life -threatening complication of high- dose chemotherapy in patients with acute myeloid leukaemia (AML). (bvsalud.org)
  • The allogeneic HSCT was the most frequently performed (57.14%) and the most used source of Hematopoietic progenitor cells (HPC) was the peripheral blood (54.29%) and 5.71% of these patients developed the Graft versus Host Disease (GVHD), of which one was affected by acute GVHD and another by chronic GVHD. (bvsalud.org)
  • AML is also called acute myelogenous leukemia and acute nonlymphocytic leukemia. (cancer.gov)
  • Among those affected, the majority develop cancer , most often acute myelogenous leukemia (AML), and 90% develop aplastic anemia (the inability to produce blood cells) by age 40. (wikipedia.org)
  • Ghiaur G, Wroblewski M, Loges S. Acute Myelogenous Leukemia and its Microenvironment: A Molecular Conversation. (medscape.com)
  • Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. (medscape.com)
  • Acute Myeloid Leukaemia (AML) is a blood cancer, which affects the red blood cells in the bone marrow. (bioinformation.net)
  • Temporal changes of the incidence of childhood B-cell precursor acute lymphoblastic leukaemia in Germany during the COVID-19 pandemic. (who.int)
  • A triple therapy combining two immune checkpoint inhibitors (ICPIs) with the standard-of-care chemotherapy, a hypomethylating agent called azacitidine, has shown promising results for treatment of relapsed or refractory acute myeloid leukemia (AML), according to findings from a Phase II study at The University of Texas MD Anderson Cancer Center . (mdanderson.org)
  • Annamycin is currently in development for the treatment of soft tissue sarcoma (STS) lung metastases and relapsed or refractory acute myeloid leukemia (AML). (wkrg.com)
  • MacroGenics has dosed the first patient in a Phase I study of MGD006 in relapsed or refractory acute myeloid leukemia (AML), marking the first clinical trial of a DART product candidate. (clinicaltrialsarena.com)
  • The global acute myeloid leukemia therapeutics market is segregated into pipeline drugs, chemotherapy drugs, and chemotherapy regimens. (grandviewresearch.com)
  • In order to further prove a potential role for FOXM1 in AML chemoresistance, we induced an FLT3-ITD-driven myeloid neoplasm in a FOXM1-overexpressing transgenic mouse model and demonstrated significantly higher residual disease after standard chemotherapy. (jci.org)
  • Acute myeloid leukemia (AML) is a heterogeneous cancer of the blood, though specific recurring cytogenetic abnormalities in AML strongly are associated with attaining complete response after induction chemotherapy, remission duration, and survival. (researchsquare.com)
  • Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. (medscape.com)
  • Twelve samples of leukemia (four acute lymphocytic leukemia, four acute myeloid leukemia (AML), four chronic lymphocytic leukemia), as well as peripheral blood mononuclear cells (PBMC) from four healthy donors were used for the compound screen. (nature.com)
  • Acute promyelocytic leukemia (APL) is a subtype of AML. (cancer.gov)
  • For example, the acute promyelocytic leukemia (APL) subtype is often treated using drugs that are different from those used for other subtypes of AML. (cancer.org)
  • These medicines are used to treat a subtype of AML called acute promyelocytic leukemia (APL). (ahealthyme.com)
  • However, pancytopenia due to acute promyelocytic leukemia (APL) is a life-threatening emergency that must be aggressively treated immediately. (medscape.com)
  • Part 2: Expansion cohort: the main purpose of this part of the clinical trial is to assess the safety and anti-leukemia activity of SEL24/MEN1703 given at the highest tolerated dose in patient with relapsed/refractory Acute Myeloid Leukemia, either all comers as well as harboring IDH1/IDH2 mutations. (clinicaltrials.gov)
  • The optimal treatment regimen for relapsed/refractory acute myeloid leukemia (AML) is unknown. (centerwatch.com)
  • In this video, Drs. Richard Stone, Courtney DiNardo, and Eunice Wang treatment options for primary refractory FLT3-ITD-positive acute myeloid leukemia (AML). (ascopost.com)
  • The American Society of Hematology (ASH) has partnered with several organizations on independent educational programming designed to help address knowledge gaps in the diagnosis and treatment of acute myeloid leukemia (AML). (hematology.org)
  • The American Society for Clinical Pathology (ASCP), the Oncology Nursing Society (ONS), the National Marrow Donor Program ® /Be The Match ® , and The France Foundation have joined ASH to create and implement a specialized curriculum, titled "Acute Myeloid Leukemia MATTERS: A Multidisciplinary Approach To Testing and Diagnosis, Evaluation of Risk, and Personalized Treatment Selection. (hematology.org)
  • North America leads the world in leukemia therapeutics treatment, given the high rates of diagnosis here. (waterskraus.com)
  • Leukemia and 25.71% had Acute Myeloid Leukemia as the main diagnosis. (bvsalud.org)
  • Andersen MK, Larson RA, Mauritzson N, Schnittger S, Jhanwar SC, Pedersen-Bjergaard J. Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop. (medscape.com)
  • Have you or a loved one been exposed to benzene and been diagnosed with acute myeloid leukemia (AML) or acute lymphocytic leukemia (ALL)? (waterskraus.com)
  • Bone marrow examination revealed de novo acute myeloid leukemia. (go.jp)
  • Although portal hypertension has been reportedly associated with myeloproliferative diseases, such as primary myelofibrosis, it has never been reportedly complicated with de novo acute myeloid leukemia. (go.jp)
  • BACKGROUND AND OBJECTIVES: The objective of this study was to investigate the expression of MDR1 and bcl-2 proteins in de novo acute myeloid leukemia (AML). (haematologica.org)
  • These cases of CN-AML are referred to as familial acute myeloid leukemia with mutated CEBPA . (medlineplus.gov)
  • Smith ML, Cavenagh JD, Lister TA, Fitzgibbon J. Mutation of CEBPA in familial acute myeloid leukemia. (medscape.com)
  • OPB‑111077 is a novel, highly specific oral signal transducer and activator of transcription 3 inhibitor that has exhibited good efficacy against solid and blood cancers, including acute myeloid leukemia (AML), in preclinical models. (spandidos-publications.com)
  • DDX41 MutGL myeloid cancers may be regarded as a separate entity, according to recent findings, even when their exact presentation and prognosis were unknown. (physiciansweekly.com)
  • Although AML makes up only about 1 percent of all cancers, it is the second most common type of leukemia diagnosed, according to the American Cancer Society. (scitechdaily.com)
  • In this cohort, elevated rates of overall and site-specific cancers were observed, including digestive, oral, respiratory, and urinary cancers as well as leukemia (Daniels et al. (cdc.gov)
  • The Company also has clinical data for the use of Zantrene as a chemotherapeutic agent with reduced cardiotoxicity in acute myeloid leukemia (AML), breast and ovarian cancers and is investigating its use in these areas. (ft.com)
  • The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. (medscape.com)
  • Rarely, an inherited mutation in the CEBPA gene causes acute myeloid leukemia. (medlineplus.gov)
  • What Causes Acute Myeloid Leukemia? (kidshealth.org)
  • This puts the leukemia into remission. (lvhn.org)
  • It begins once the leukemia is in remission. (lvhn.org)
  • At present, the Leukemia & Lymphoma Society (LLS) estimates that there are 381,774 people in the U.S. who are either still battling leukemia or are in remission from it. (pepid.com)
  • The possibility that ROLVEDON acts as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia, diseases for which ROLVEDON is not approved, cannot be excluded. (rolvedon.com)
  • Glucocorticoid treatment can ameliorate effects of graft-versus-host disease and promote graft-versus-leukemia effects in pre-clinical models. (fredhutch.org)
  • [ 1 ] The number continues to increase by 10-20% annually, and reductions in organ damage, infection, and severe, acute graft versus host disease (GVHD) seem to be contributing to improved outcomes. (medscape.com)
  • The global acute myeloid leukemia therapeutics market is anticipated to gain lucrative growth over the forecast period as a consequence of rising incidences of acute myeloid leukemia (AML)and its relapse cases across the globe. (grandviewresearch.com)
  • Moreover, higher chances of early identification of leukemia cells, targeted therapy, and reduced chances of relapse of the acute myeloid leukemia are further expected to boost of the forecast period. (grandviewresearch.com)
  • Its purpose is to kill any remaining leukemia cells that may not be active but could begin to regrow and cause a relapse. (lvhn.org)
  • Rising incidences of acute myeloid leukemia therapeutics are attributed to factors such as genetic mutations, unhealthy lifestyles, continued exposure to hazardous chemicals such as benzene, and radiation exposure. (grandviewresearch.com)
  • A study shows blood donors that do not have cancer including leukemia, 10% over 65 who donated find genetic changes commonly that are commonly found in AML. (nbmtlink.org)
  • The most frequent genetic susceptibility to myelodysplastic syndrome and acute myeloid leukemia (AML) is DDX41 germline mutations (DDX41 MutGL ). (physiciansweekly.com)
  • Pediatric acute myeloid leukemia is a heterogeneous illness with numerous subtypes primarily based on genetic, medical, transcriptional, and epigenomic elements. (chores4kids.com)
  • Alterations in myeloid transcription factors governing hematopoietic differentiation provide second necessary event for leukemogenesis. (genome.jp)
  • Acute myeloid leukemia (AML) is a heterogeneous clonal hematopoietic progenitor cell disorder characterized by immature myeloid cell proliferation and bone marrow failure, exhibiting a spectrum of morphological, immunophenotypic, cytogenetic and molecular characteristics ( 1 ). (spandidos-publications.com)
  • AML is a type of hematological malignancy associated with the malignant transformation of hematopoietic stem cells, which generate blood cells, into leukemia cells. (sonosite.com)
  • Myelodysplasticsyndrome (MDS) and acute myeloid leukemia (AML) are clonal hematopoietic stem cell diseases leading to an insufficient formation of functional blood cells. (nih.gov)
  • While many people do well with initial treatment for acute myeloid leukemia (AML) , some require more treatment. (verywellhealth.com)
  • This is important because treatment varies among different types of leukemia. (kidshealth.org)
  • Assistance with the prescription drugs and biologics used in the treatment of acute myeloid leukemia. (healthwellfoundation.org)
  • The results suggest that quinacrine have repositioning potential for treatment of acute myeloid leukemia by targeting of ribosomal biogenesis. (nature.com)
  • There are many treatment choices for acute myeloid leukemia (AML). (ahealthyme.com)
  • Focusing first on GVHD, PT-Cy treatment performed better at preventing acute GVHD than glucocorticoids, however chronic levels of GVHD were similar. (fredhutch.org)
  • In this webcast, experts examine advances in the treatment of acute myeloid leukemia (AML). (primeinc.org)
  • New drugs for treatment of acute myeloid leukemia, also known as AML, continue to be developed by a number of pharmaceutical companies. (waterskraus.com)
  • Measure bcl-2 and related antiapoptotic and proapoptotic proteins in circulating and/or marrow leukemia cells before, during, and after treatment with G3139. (knowcancer.com)
  • On July 20, 2018, the U.S. Food and Drug Administration (FDA) approved the first acute myeloid leukemia treatment. (pepid.com)
  • Despite enduring complications and undergoing two transplants, Brown’s treatment was a success: he was cured both of his leukemia and HIV infection. (virology.ws)
  • Others - like Sweden's Meda - may also be relatively unaffected as - due to Bev Venue's position as the world's only supplier of the acute myeloid leukemia treatment Ceplene - mean the EMA has opted not to ask for a recall. (outsourcing-pharma.com)
  • Nevertheless treatment with 5-aza-2´- deoxycytidine enhanced HLA-G transcription and concomitantly HLA-G protein synthesis in some leukemia cells. (elis.sk)
  • A hematologist details the frontline treatment options and goals in acute myeloid leukemia and describes venetoclax. (targetedonc.com)
  • Researchers revealed new insights into how acute myeloid leukemia (AML) develops and progresses, according to a study published in Molecular Cell on July 20, 2021 . (uchospitals.edu)
  • In a latest research printed in Nature Communications , researchers used ribonucleic acid (RNA) sequence information to know the affiliation between inflammatory cytokines and poor outcomes of pediatric Acute Myeloid Leukemia (pAML). (chores4kids.com)
  • Adult acute myeloid leukemia (AML) is a type of cancer in which the bone marrow makes a large number of abnormal blood cells. (cancer.gov)
  • Cytogenetically normal acute myeloid leukemia (CN-AML) is one form of a cancer of the blood-forming tissue (bone marrow) called acute myeloid leukemia. (medlineplus.gov)
  • Leukemia is a cancer that mostly affects white blood cells. (kidshealth.org)
  • Leukemia is the most common type of cancer in children. (kidshealth.org)
  • Doctors carefully look at the cancer cells and figure out the type and subtype of the leukemia. (kidshealth.org)
  • Scientists at the Department of Medicine, Albert Einstein College of Medicine, NY have discovered a new molecule which kills resistant cancer cells in acute myeloid leukemia. (medindia.net)
  • Scientists discover that a molecule called BTSA1 can kill resistant cancer cells through apoptosis in acute myeloid leukemia but spare healthy cells. (medindia.net)
  • Researchers at the University of Chicago Medicine Comprehensive Cancer Center and their collaborators were interested in learning how mutant IDH2 drives the development of AML, and how the leukemia cells are able to regulate the production of 2-HG to promote spread and avoid cell death. (uchospitals.edu)
  • Smith RE, Bryant J, DeCillis A, Anderson S. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. (medscape.com)
  • One trial is the first conducted in leukemia of a rising type of cancer immunotherapy called immune checkpoint blockade. (mdanderson.org)
  • These mutations include internal tandem duplications (ITD)*3 and tyrosine kinase domain (TKD)*4, which induce abnormal growth of leukemia cells and are associated with poor prognosis. (sonosite.com)
  • FRENCHTOWN, NJ / ACCESSWIRE / September 23, 2022 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor Innovations in Acute Myeloid Leukemia Spotlight Event featuring Moleculin Biotech on Wednesday, September 28, 2022 at 11:00 AM ET. (wkrg.com)
  • The histone deacetylase (HDAC) inhibitor panobinostat potentiates anthracycline and cytarabine cytotoxicity in acute myeloid leukemia (AML) cells. (nih.gov)
  • The advent of upcoming therapies including farnesyltransferase inhibitors, immunotoxins, alkylating agents, monoclonal antibodies , FMS-like tyrosine kinase 3 inhibitors, and multidrug-resistant modulators are anticipated to upsurge the acute myeloid leukemia (AML)market growth. (grandviewresearch.com)
  • This is why there is a growing focus on FLT3 inhibitors which can suppress the replication of leukemia cells by inhibiting the activity of the mutated FLT3. (sonosite.com)
  • In cellular experiments, FF-10101 showed strong inhibitory activities against the proliferation of leukemia cells expressing TKD mutations conferring resistance to other FLT3 inhibitors. (sonosite.com)
  • In AML, the myeloid stem cells usually become a type of immature white blood cell called myeloblasts (or myeloid blasts ). (cancer.gov)
  • These abnormal white blood cells, red blood cells, or platelets are also called leukemia cells or blasts. (cancer.gov)
  • the bone marrow makes large numbers of abnormal, immature white blood cells called myeloid blasts. (medlineplus.gov)
  • Instead of developing into normal white blood cells, the myeloid blasts develop into cancerous leukemia cells. (medlineplus.gov)
  • These cells, called myeloid (MYE-uh-loyd) blasts, can't mature into normal white blood cells. (kidshealth.org)
  • Acute myeloid leukemia (AML) is a disease that is characterized by uncontrolled proliferation of clonal neoplastic cells and accumulation in the bone marrow of blasts with an impaired differentiation program. (genome.jp)
  • Juvenile myelomonocytic (mye-uh-low-mon-uh-SIT-ik) leukemia (JMML) happens when immature blood cells (called blasts) make too many myelocytes and monocytes (two types of white blood cells. (kidshealth.org)
  • Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. (bvsalud.org)
  • A blood stem cell may become a myeloid stem cell or a lymphoid stem cell. (cancer.gov)
  • With leukemia (loo-KEE-mee-uh), the bone marrow makes white blood cells that don't work. (kidshealth.org)
  • It has been shown to increase maturation of leukemia cells and reduce the number of leukemic cells in animal models. (uchospitals.edu)
  • FF-10101 inhibits FLT3 activity by binding irreversibly with an amino acid in FLT3, suppressing the abnormal growth of leukemia cells. (sonosite.com)
  • In 2010, 62 percent of leukemia drugs in the therapeutics market were sold in North America. (waterskraus.com)
  • Most kids and teens treated for leukemia are cured of the disease. (kidshealth.org)
  • The serine/threonine kinase mammalian target of rapamycin (mTOR) is crucial for cell growth and proliferation, and is constitutively activated in primary acute myeloid leukemia (AML) cells, therefore representing a major target for drug development in this disease. (crick.ac.uk)
  • In this video, Drs. Richard Stone, Courtney DiNardo, and Eunice Wang discuss therapy options for minimal residual disease (MRD)-positive acute myeloid leukemia (AML). (ascopost.com)
  • It is the most common type of acute leukemia in adults. (cancer.gov)
  • It is the most common acute leukemia in adults and usually gets worse quickly if it is not treated. (uchospitals.edu)
  • Defining and Treating Older Adults with Acute Myeloid Leukemia Who Are Ineligible for Intensive Therapies. (uchicago.edu)
  • AML is a particularly concerning form of leukemia in adults, as it progresses rapidly and has a 27.4% survival rate overall - the lowest number among all types of leukemia. (pepid.com)
  • Acute myeloid leukemia (AML) is the most common acute leukemia in adults . (bvsalud.org)
  • Leukemia usually occurs in middle age and progresses as the patient ages. (waterskraus.com)
  • Failure to rapidly distinguish a patient with acute myeloid leukemia (AML) from a patient with a less urgent hematologic disorder is the most important medicolegal pitfall in this setting. (medscape.com)
  • Daniel Pollyea, MD, MS, explains the risk factors for acute myeloid leukemia, the importance of biomarker testing, and the challenges that prevent every patient from being tested. (targetedonc.com)
  • This photomicrograph reveals some of the histopathology seen in a bone marrow specimen extracted from a patient diagnosed with acute myeloid leukemia (AML). (cdc.gov)
  • This leukemia occurs when genes on chromosome 15 switch places with some genes on chromosome 17 and an abnormal gene called PML-RARA is made. (cancer.gov)
  • Transcription factor fusion proteins such as AML-ETO, PML-RARalpha or PLZF-RARalpha block myeloid cell differentiation by repressing target genes. (genome.jp)
  • This discrepancy in sensitivity to hymeglusin may be attributed to the positive increase in the expression levels of HMGCS1 and multiple upregulated pro-leukemia genes in KG-1 cells. (frontiersin.org)
  • Leukemia may affect red blood cells, white blood cells, and platelets. (cancer.gov)
  • Leukemia cells can build up in the bone marrow and blood so there is less room for healthy white blood cells, red blood cells, and platelets. (cancer.gov)
  • The leukemia cells can spread outside the blood to other parts of the body, including the central nervous system (brain and spinal cord ), skin, and gums . (cancer.gov)
  • Sometimes leukemia cells form a solid tumor called a myeloid sarcoma . (cancer.gov)
  • In the 1970s, a group of French, American, and British leukemia experts divided AML into subtypes, M0 through M7, based on the type of cell the leukemia develops from and how mature the cells are. (cancer.org)
  • This was based largely on how the leukemia cells looked under the microscope after routine staining. (cancer.org)
  • There were, unfortunately, too many remaining leukemia cells. (verywellhealth.com)
  • With a stem cell transplant, after bone marrow that has any leukemia cells is first destroyed, it is then replaced with stem cells capable of developing into AML-free bone marrow. (verywellhealth.com)
  • By blocking this, it can allow the leukemia cells to better differentiate. (verywellhealth.com)
  • Acute myeloid leukemia (AML) happens when the body makes too many immature blood cells. (kidshealth.org)
  • Because their white blood cells can't fight infections, kids with leukemia are more likely to get viral or bacterial infections. (kidshealth.org)
  • Doctors use these to rule out other causes of symptoms, or look for a mass of leukemia cells in the chest that can affect breathing or blood circulation. (kidshealth.org)
  • Acute myeloid leukemia (AML) starts in the bone marrow (the soft inner part of certain bones, where new blood cells are made), but in most cases it quickly moves into the blood. (healthwellfoundation.org)
  • These myeloblasts, or leukemia cells, are abnormal and do not become healthy white blood cells. (lvhn.org)
  • The leukemia cells can build up in the blood and bone marrow so there is less room for healthy cells. (lvhn.org)
  • Its purpose is to kill the leukemia cells in the blood and bone marrow. (lvhn.org)
  • In the present study 12 samples of leukemia and 4 samples of normal mononuclear cells were tested in response to 1266 mechanistically annotated compounds including Food and Drug Administration-approved drugs. (nature.com)
  • Quinacrine was the only compound found with activity in the three leukemia subtypes tested with concurrent low toxicity in normal mononuclear cells, and was, therefore, selected for further preclinical evaluation. (nature.com)
  • 2-HG blocks the maturation of white blood cells, driving the development of leukemia. (uchospitals.edu)
  • The mechanisms by which AML develops are not completely understood, but it is generally believed to begin in the hemopoietic stem cells or progenitors, which develop into myeloid cells and in turn go on to become red blood cells, white blood cells or platelets. (scitechdaily.com)
  • These leukemia cells then exhibit abnormal growth in the bone marrow and it prevents the generation of blood cells. (sonosite.com)
  • Furthermore, the leukemia cells with aberrant growth invade other organs outside the bone marrow, resulting in various functional disorders. (sonosite.com)
  • Bone marrow failure due to acute myeloid leukemia (AML) is a significant factor behind the disease's high rate of morbidity and mortality. (scitechdaily.com)
  • Mortality from leukemia was associated with duration of employment among styrene-exposed workers, such as those in the boatbuilding industry (Ruder et al. (cdc.gov)
  • Leukemia and Lymphoma Society , 3 Mar. 2015, org/node/22231#Leukemia . (pepid.com)